NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation
These statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2019. In the opinion of management, the accompanying unaudited Consolidated Financial Statements of The Procter & Gamble Company and subsidiaries (the "Company," "Procter & Gamble," "P&G," "we" or "our") contain all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods reported. However, the results of operations included in such financial statements may not necessarily be indicative of annual results.
2. New Accounting Pronouncements and Policies
On July 1, 2019, we adopted ASU 2016-02, "Leases (Topic 842)." The new accounting standard requires the recognition of right-of-use assets and lease liabilities for all long-term leases, including operating leases, on the balance sheet. We elected the optional transition method and adopted the new guidance on a modified retrospective basis with no restatement of prior period amounts. As allowed under the new accounting standard, we elected to apply practical expedients to carry forward the original lease determinations, lease classifications and accounting of initial direct costs for all asset classes at the time of adoption. The adoption did not have a material impact on our financial statements, resulting in an increase of approximately 1% to each of our total assets and total liabilities on our balance sheet as of July 1, 2019. See Note 10 for further information.
In January 2017, the FASB issued ASU 2017-04, "Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment." The standard simplifies the accounting for goodwill impairment by requiring a goodwill impairment to be measured using a single step impairment model, whereby the impairment equals the difference between the carrying amount and the estimated fair value of the specified reporting units in their entirety. This eliminates the second step of the current impairment model that requires companies to first estimate the fair value of all assets in a reporting unit and measure impairments based on those estimated fair values and a residual measurement approach. It also specifies that any loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. We will adopt the standard effective July 1, 2020. The impact of the new standard will be dependent on the specific facts and circumstances of future individual impairments, if any.
In March 2020, the FASB issued ASU 2020-04, "Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting." The amendments provide optional guidance for a limited time to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts and hedging relationships that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. These amendments are effective immediately and may be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before December 31, 2022. We are currently evaluating our contracts and the optional expedients provided by the new standard.
No other new accounting pronouncement issued or effective during the fiscal year had, or is expected to have, a material impact on our Consolidated Financial Statements.
3. Segment Information
Under U.S. GAAP, our operating segments are aggregated into five reportable segments: 1) Beauty, 2) Grooming, 3) Health Care, 4) Fabric & Home Care and 5) Baby, Feminine & Family Care. Our five reportable segments are comprised of:
•Beauty: Hair Care (Conditioner, Shampoo, Styling Aids, Treatments); Skin and Personal Care (Antiperspirant and Deodorant, Personal Cleansing, Skin Care);
•Grooming: Shave Care (Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Shave Care); Appliances
•Health Care: Oral Care (Toothbrushes, Toothpaste, Other Oral Care); Personal Health Care (Gastrointestinal, Rapid Diagnostics, Respiratory, Vitamins/Minerals/Supplements, Pain Relief, Other Personal Health Care);
•Fabric & Home Care: Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents); Home Care (Air Care, Dish Care, P&G Professional, Surface Care); and
•Baby, Feminine & Family Care: Baby Care (Baby Wipes, Taped Diapers and Pants); Feminine Care (Adult Incontinence, Feminine Care); Family Care (Paper Towels, Tissues, Toilet Paper).
Amounts in millions of dollars unless otherwise specified.
Our operating segments are comprised of similar product categories. Operating segments that individually accounted for 5% or more of consolidated net sales are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
% of Net sales by operating segment (1)
|
|
|
|
|
|
|
|
|
Three Months Ended March 31
|
|
|
|
Nine Months Ended March 31
|
|
|
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
Fabric Care
|
23%
|
|
|
22%
|
|
|
23%
|
|
|
23%
|
|
|
Baby Care
|
11%
|
|
|
12%
|
|
|
11%
|
|
|
12%
|
|
|
Home Care
|
11%
|
|
|
11%
|
|
|
10%
|
|
|
10%
|
|
|
Skin and Personal Care
|
9%
|
|
|
10%
|
|
|
10%
|
|
|
10%
|
|
|
Hair Care
|
9%
|
|
|
9%
|
|
|
9%
|
|
|
9%
|
|
|
Family Care
|
9%
|
|
|
8%
|
|
|
9%
|
|
|
9%
|
|
|
Oral Care
|
8%
|
|
|
8%
|
|
|
8%
|
|
|
8%
|
|
|
Shave Care
|
7%
|
|
|
8%
|
|
|
7%
|
|
|
8%
|
|
|
Feminine Care
|
7%
|
|
|
6%
|
|
|
6%
|
|
|
6%
|
|
|
Personal Health Care
|
5%
|
|
|
5%
|
|
|
5%
|
|
|
4%
|
|
|
Other
|
1%
|
|
|
1%
|
|
|
2%
|
|
|
1%
|
|
|
Total
|
100%
|
|
|
100%
|
|
|
100%
|
|
|
100%
|
|
(1)% of Net sales by operating segment excludes sales held in Corporate.
Following is a summary of reportable segment results:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31
|
|
|
|
|
|
Nine Months Ended March 31
|
|
|
|
|
|
|
|
Net Sales
|
|
Earnings/(Loss) Before Income Taxes
|
|
Net Earnings
|
|
Net Sales
|
|
Earnings/(Loss) Before Income Taxes
|
|
Net Earnings
|
|
Beauty
|
2020
|
$
|
3,033
|
|
|
$
|
553
|
|
|
$
|
436
|
|
|
$
|
10,183
|
|
|
$
|
2,717
|
|
|
$
|
2,168
|
|
|
|
2019
|
3,061
|
|
|
675
|
|
|
551
|
|
|
9,707
|
|
|
2,586
|
|
|
2,082
|
|
|
Grooming
|
2020
|
1,380
|
|
|
305
|
|
|
254
|
|
|
4,559
|
|
|
1,225
|
|
|
1,018
|
|
|
|
2019
|
1,424
|
|
|
329
|
|
|
344
|
|
|
4,603
|
|
|
1,194
|
|
|
1,062
|
|
|
Health Care
|
2020
|
2,262
|
|
|
523
|
|
|
408
|
|
|
7,013
|
|
|
1,795
|
|
|
1,380
|
|
|
|
2019
|
2,115
|
|
|
462
|
|
|
358
|
|
|
6,180
|
|
|
1,571
|
|
|
1,210
|
|
|
Fabric & Home Care
|
2020
|
5,826
|
|
|
1,271
|
|
|
957
|
|
|
17,445
|
|
|
3,887
|
|
|
2,960
|
|
|
|
2019
|
5,382
|
|
|
1,114
|
|
|
847
|
|
|
16,427
|
|
|
3,392
|
|
|
2,584
|
|
|
Baby, Feminine & Family Care
|
2020
|
4,597
|
|
|
1,130
|
|
|
859
|
|
|
13,746
|
|
|
3,340
|
|
|
2,552
|
|
|
|
2019
|
4,357
|
|
|
861
|
|
|
653
|
|
|
13,305
|
|
|
2,693
|
|
|
2,052
|
|
|
Corporate
|
2020
|
116
|
|
|
(284)
|
|
|
43
|
|
|
306
|
|
|
(591)
|
|
|
239
|
|
|
|
2019
|
123
|
|
|
(163)
|
|
|
23
|
|
|
368
|
|
|
(302)
|
|
|
213
|
|
|
Total Company
|
2020
|
$
|
17,214
|
|
|
$
|
3,498
|
|
|
$
|
2,957
|
|
|
$
|
53,252
|
|
|
$
|
12,373
|
|
|
$
|
10,317
|
|
|
|
2019
|
16,462
|
|
|
3,278
|
|
|
2,776
|
|
|
50,590
|
|
|
11,134
|
|
|
9,203
|
|
4. Goodwill and Other Intangible Assets
Goodwill is allocated by reportable segment as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Beauty
|
|
Grooming
|
|
Health Care
|
|
Fabric & Home Care
|
|
Baby, Feminine & Family Care
|
|
Total Company
|
|
Goodwill at June 30, 2019
|
$
|
12,985
|
|
|
$
|
12,881
|
|
|
$
|
7,972
|
|
|
$
|
1,855
|
|
|
$
|
4,580
|
|
|
$
|
40,273
|
|
|
Acquisitions and divestitures
|
(1)
|
|
|
—
|
|
|
(46)
|
|
|
—
|
|
|
5
|
|
|
(42)
|
|
|
Translation and other
|
(189)
|
|
|
(143)
|
|
|
(201)
|
|
|
(23)
|
|
|
(58)
|
|
|
(614)
|
|
|
Goodwill at March 31, 2020
|
$
|
12,795
|
|
|
$
|
12,738
|
|
|
$
|
7,725
|
|
|
$
|
1,832
|
|
|
$
|
4,527
|
|
|
$
|
39,617
|
|
Amounts in millions of dollars unless otherwise specified.
Goodwill from current year acquisitions and divestitures primarily reflects opening balance sheet adjustments from the prior year acquisition of the over-the-counter (OTC) healthcare business of Merck KGaA (Merck OTC) in the Health Care reportable segment (see Note 12), along with a minor Baby Care acquisition in the current year and adjustments from a prior year Beauty acquisition.
Identifiable intangible assets at March 31, 2020 were comprised of:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Carrying Amount
|
|
Accumulated Amortization
|
|
Intangible assets with determinable lives
|
$
|
8,458
|
|
|
$
|
(5,628)
|
|
|
Intangible assets with indefinite lives
|
21,004
|
|
|
—
|
|
|
Total identifiable intangible assets
|
$
|
29,462
|
|
|
$
|
(5,628)
|
|
Intangible assets with determinable lives consist of brands, patents, technology and customer relationships. The intangible assets with indefinite lives consist of brands. The amortization expense of determinable lived intangible assets for the three months ended March 31, 2020 and 2019 was $87 and $98, respectively. For the nine months ended March 31, 2020 and 2019, the amortization expense was $274 and $252, respectively.
Goodwill and indefinite lived intangible assets are not amortized but are tested annually for impairment. The test to evaluate goodwill for impairment is a two-step process. In the first step, we compare the fair value of the reporting unit to its carrying value. If the fair value of the reporting unit is less than the carrying value, we perform a second step (the step two testing) to determine the implied fair value of the reporting unit's goodwill. The step two testing of the impairment analysis requires a valuation of a reporting unit's tangible and intangible assets and liabilities in a manner similar to the allocation of purchase price in a business combination. If the resulting implied fair value of the reporting unit's goodwill is less than its carrying value, that difference represents an impairment.
The business unit valuations used to test goodwill and intangible assets for impairment are dependent on a number of significant estimates and assumptions, including macroeconomic conditions, overall category growth rates, competitive activities, cost containment, margin expansion and Company business plans. We believe these estimates and assumptions are reasonable. However, future changes in the judgments, assumptions and estimates that are used in our impairment testing for goodwill and indefinite-lived intangible assets, including discount and tax rates or future cash flow projections, could result in significantly different estimates of the fair values. Our annual impairment testing for goodwill and indefinite lived intangible assets occurs during the three months ended December 31.
Most of our goodwill reporting units are comprised of a combination of legacy and acquired businesses and as a result have fair value cushions that, at a minimum, exceed two times their underlying carrying values. Certain of our goodwill reporting units, in particular Shave Care and Appliances, are comprised entirely of acquired businesses and as a result, have fair value cushions that are not as high. The Appliances reporting unit has a fair value that significantly exceeds the underlying carrying value. As previously disclosed, the carrying value of the Shave Care reporting unit and the related Gillette indefinite-lived intangible asset were impaired during the quarter ended June 30, 2019. The underlying reductions in fair values were due in large part to significant currency devaluations in a number of countries relative to the U.S. dollar, a deceleration of category growth caused by changing grooming habits, primarily in the developed markets, and an increased competitive market environment in the U.S. and certain other markets. As a result of the June 30, 2019 impairment determined by the step two testing, the Shave Care fair value exceeded the carrying value by approximately 20% as of June 30, 2019. Because the impairment testing for intangible assets is a one-step process, the Gillette indefinite-lived intangible asset fair value approximated its carrying value at that date. During our annual impairment testing during the quarter ended December 31, 2019, we reduced the discount rate used in the valuation based on developments in the macroeconomic environment. As a result of this change and updates to other underlying cash flow projections, the Shave Care fair value exceeded the carrying value by more than 20% and the Gillette indefinite-lived intangible asset fair value exceeded the carrying value by approximately 5%. The Gillette indefinite-lived intangible asset is most susceptible to future impairment risk.
The most significant assumptions utilized in the determination of the estimated fair values of Shave Care reporting unit and the Gillette indefinite-lived intangible asset are the net sales and earnings growth rates (including residual growth rates) and discount rate. The residual growth rate represents the expected rate at which the reporting unit and Gillette brand are expected to grow beyond the shorter-term business planning period. The residual growth rate utilized in our fair value estimates is consistent with the reporting unit and brand operating plans and approximates expected long term category market growth rates. The residual growth rate is dependent on overall market growth rates, the competitive environment, inflation, relative currency exchange rates and business activities that impact market share. As a result, the residual growth rate could be adversely impacted by a sustained deceleration in category growth, grooming habit changes, devaluation of currencies against the U.S. dollar or an increased competitive environment. The discount rate, which is consistent with a weighted average cost of capital that is likely to be expected by a market participant, is based upon industry required rates of return, including consideration of both debt and equity components of the capital structure. Our discount rate may be impacted by adverse changes in the
Amounts in millions of dollars unless otherwise specified.
macroeconomic environment, volatility in the equity and debt markets or other country specific factors, such as further devaluation of currencies against the U.S. dollar. Spot rates as of the fair value measurement date are utilized in our fair value estimates for cash flows outside the U.S.
While management can and has implemented strategies to address these events, changes in operating plans or adverse changes in the business or in the macroeconomic environment in the future could reduce the underlying cash flows used to estimate fair values and could result in a decline in fair value that would trigger future impairment charges of the Shave Care reporting unit's goodwill and indefinite-lived intangibles. As of March 31, 2020, the carrying values of the Shave Care goodwill and the Gillette indefinite-lived intangible asset were $12.4 billion and $14.1 billion, respectively.
The duration and severity of the COVID-19 pandemic could result in additional future impairment charges for the Shave Care reporting unit goodwill and the Gillette indefinite-lived intangible asset. While we have concluded that a triggering event did not occur during the quarter ended March 31, 2020, a prolonged pandemic could impact the results of operations due to changes to assumptions utilized in the determination of the estimated fair values of Shave Care reporting unit and the Gillette indefinite-lived intangible asset that are significant enough to trigger an impairment. Net sales and earnings growth rates could be negatively impacted by reductions or changes in demand for our shave care products, which may be caused by, among other things: the temporary inability of consumers to purchase our products due to illness, quarantine or other travel restrictions, or financial hardship, or by shifts in demand away from one or more of our higher priced products to lower priced products. In addition, relative global and country/regional macroeconomic factors could result in additional and prolonged devaluation of other countries’ currencies relative to the dollar. Finally, the discount rate utilized in our valuation model could be impacted by changes in the underlying interest rates and risk premiums included in the determination of the cost of capital.
The table below provides a sensitivity analysis for the Shave Care reporting unit and the Gillette indefinite lived intangible asset, utilizing reasonably possible changes in the assumptions for the shorter term and residual growth rates and the discount rate, to demonstrate the potential impacts to the estimated fair values. The table below provides, in isolation, the estimated fair value impacts related to a 25 basis-point increase in the discount rate or a 25 basis-point decrease in our shorter-term and residual growth rates, either of which, in isolation, would result in an additional impairment of the Gillette indefinite-lived intangible asset.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Approximate Percent Change in Estimated Fair Value
|
|
|
|
|
+25 bps Discount Rate
|
|
-25 bps Growth Rates
|
|
Shave Care goodwill reporting unit
|
(6)
|
%
|
|
(6)
|
%
|
|
Gillette indefinite-lived intangible asset
|
(6)
|
%
|
|
(6)
|
%
|
Amounts in millions of dollars unless otherwise specified.
5. Earnings Per Share
Basic net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble less preferred dividends by the weighted average number of common shares outstanding during the period. Diluted net earnings per common share are calculated using the treasury stock method, on the basis of the weighted average number of common shares outstanding plus the dilutive effect of stock options and other stock-based awards and the assumed conversion of preferred stock.
Net earnings per share were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CONSOLIDATED AMOUNTS
|
Three Months Ended March 31
|
|
|
|
Nine Months Ended March 31
|
|
|
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
Net earnings
|
$
|
2,957
|
|
|
$
|
2,776
|
|
|
$
|
10,317
|
|
|
$
|
9,203
|
|
|
Less: Net earnings attributable to noncontrolling interests
|
40
|
|
|
31
|
|
|
90
|
|
|
65
|
|
|
Net earnings attributable to P&G (Diluted)
|
2,917
|
|
|
2,745
|
|
|
10,227
|
|
|
9,138
|
|
|
Preferred dividends
|
(64)
|
|
|
(64)
|
|
|
(193)
|
|
|
(195)
|
|
|
Net earnings attributable to P&G available to common shareholders (Basic)
|
$
|
2,853
|
|
|
$
|
2,681
|
|
|
$
|
10,034
|
|
|
$
|
8,943
|
|
|
|
|
|
|
|
|
|
|
|
SHARES IN MILLIONS
|
|
|
|
|
|
|
|
|
Basic weighted average common shares outstanding
|
2,476.2
|
|
|
2,509.1
|
|
|
2,489.1
|
|
|
2,501.5
|
|
|
Add: Effect of dilutive securities
|
|
|
|
|
|
|
|
|
Conversion of preferred shares (1)
|
85.5
|
|
|
89.6
|
|
|
86.4
|
|
|
90.8
|
|
|
Impact of stock options and other unvested equity awards (2)
|
51.6
|
|
|
39.0
|
|
|
54.8
|
|
|
32.0
|
|
|
Diluted weighted average common shares outstanding
|
2,613.3
|
|
|
2,637.7
|
|
|
2,630.3
|
|
|
2,624.3
|
|
|
|
|
|
|
|
|
|
|
|
NET EARNINGS PER SHARE (3)
|
|
|
|
|
|
|
|
|
Basic
|
$
|
1.15
|
|
|
$
|
1.07
|
|
|
$
|
4.03
|
|
|
$
|
3.58
|
|
|
Diluted
|
$
|
1.12
|
|
|
$
|
1.04
|
|
|
$
|
3.89
|
|
|
$
|
3.48
|
|
(1)Despite being included currently in Diluted net earnings per common share, the actual conversion to common stock occurs when the preferred shares are sold. Shares may only be sold after being allocated to the ESOP participants pursuant to the repayment of the ESOP's obligations through 2035.
(2)Weighted average outstanding stock options of approximately 7 million and 4 million for the three months ended March 31, 2020 and 2019, and approximately 3 million and 25 million for the nine months ended March 31, 2020 and 2019 respectively, were not included in the Diluted net earnings per share calculation because the options were out of the money or to do so would have been antidilutive (i.e., the total proceeds upon exercise would have exceeded the market value of the underlying common shares).
(3)Net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
6. Share-Based Compensation and Postretirement Benefits
The following table provides a summary of our share-based compensation expense and postretirement benefit costs:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31
|
|
|
|
Nine Months Ended March 31
|
|
|
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
Share-based compensation expense
|
$
|
123
|
|
|
|
$
|
118
|
|
|
$
|
325
|
|
|
$
|
299
|
|
|
Net periodic benefit cost for pension benefits (1)
|
42
|
|
|
30
|
|
|
126
|
|
|
94
|
|
|
Net periodic benefit cost/(credit) for other retiree benefits (1)
|
(52)
|
|
|
(41)
|
|
|
(156)
|
|
|
(124)
|
|
(1)The components of the total net periodic benefit cost for both pension benefits and other retiree benefits for these interim periods, on an annualized basis, do not differ materially from the amounts disclosed in the Annual Report on Form 10-K for the fiscal year ended June 30, 2019.
Amounts in millions of dollars unless otherwise specified.
7. Risk Management Activities and Fair Value Measurements
As a multinational company with diverse product offerings, we are exposed to market risks, such as changes in interest rates, currency exchange rates and commodity prices. There have been no significant changes in our risk management policies or activities during the nine months ended March 31, 2020.
The Company has not changed its valuation techniques used in measuring the fair value of any financial assets and liabilities during the period. The Company recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers between levels during the periods presented. Also, there was no significant activity within the Level 3 assets and liabilities during the periods presented. There were no significant assets or liabilities that were remeasured at fair value on a non-recurring basis for the nine months ended March 31, 2020.
Other investments had a fair value of $50 and $169 as of March 31, 2020 and June 30, 2019, respectively, and are presented in Other noncurrent assets. During the nine months ended March 31, 2020, the Company sold all of its existing U.S. government securities and corporate bond securities. Such securities were presented in Available-for-sale investment securities at June 30, 2019, and had fair values of $3,648 and $2,400, respectively. The Company's investments measured at fair value are generally classified as Level 2 within the fair value hierarchy. Cash equivalents were $14,171 and $2,956 as of March 31, 2020 and June 30, 2019, respectively, and are classified as Level 1 within the fair value hierarchy. There are no other material investment balances classified as Level 1 or Level 3 within the fair value hierarchy or using net asset value as a practical expedient. Fair values are generally estimated based upon quoted market prices for similar instruments.
The fair value of long-term debt was $28,602 and $25,378 as of March 31, 2020 and June 30, 2019, respectively. This includes the current portion of long-term debt instruments ($3,473 and $3,390 as of March 31, 2020 and June 30, 2019, respectively). Certain long-term debt (debt designated as a fair value hedge) is recorded at fair value. All other long-term debt is recorded at amortized cost but is measured at fair value for disclosure purposes. We consider our debt to be Level 2 in the fair value hierarchy. Fair values are generally estimated based on quoted market prices for identical or similar instruments.
Disclosures about Financial Instruments
The notional amounts and fair values of financial instruments used in hedging transactions as of March 31, 2020 and June 30, 2019 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Notional Amount
|
|
|
|
Fair Value Asset
|
|
|
|
Fair Value (Liability)
|
|
|
|
|
March 31, 2020
|
|
June 30, 2019
|
|
March 31, 2020
|
|
June 30, 2019
|
|
March 31, 2020
|
|
June 30, 2019
|
|
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate contracts
|
$
|
7,015
|
|
|
$
|
7,721
|
|
|
$
|
232
|
|
|
$
|
177
|
|
|
$
|
—
|
|
|
$
|
(1)
|
|
|
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency interest rate contracts
|
$
|
3,279
|
|
|
$
|
3,157
|
|
|
$
|
69
|
|
|
$
|
35
|
|
|
$
|
(10)
|
|
|
$
|
(24)
|
|
|
TOTAL DERIVATIVES DESIGNATED AS HEDGING INSTRUMENTS
|
$
|
10,294
|
|
|
$
|
10,878
|
|
|
$
|
301
|
|
|
$
|
212
|
|
|
$
|
(10)
|
|
|
$
|
(25)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency contracts
|
$
|
6,001
|
|
|
$
|
6,431
|
|
|
$
|
47
|
|
|
$
|
27
|
|
|
$
|
(76)
|
|
|
$
|
(20)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
TOTAL DERIVATIVES AT FAIR VALUE
|
$
|
16,295
|
|
|
$
|
17,309
|
|
|
$
|
348
|
|
|
$
|
239
|
|
|
$
|
(86)
|
|
|
$
|
(45)
|
|
All derivative assets are presented in Prepaid expenses and other current assets or Other noncurrent assets. All derivative liabilities are presented in Accrued and other liabilities or Other noncurrent liabilities.
The fair value of the interest rate derivative asset/(liability) directly offsets the cumulative amount of the fair value hedging adjustment included in the carrying amount of the underlying debt obligation. The carrying amount of the underlying debt obligation, which includes the unamortized discount or premium and the fair value adjustment, was $7,217 and $7,860 as of March 31, 2020 and June 30, 2019, respectively. In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The carrying value of those debt instruments designated as net investment hedges, which includes the adjustment for the foreign currency transaction gain or loss on those instruments, was $16,765 and $17,154 as of March 31, 2020 and June 30, 2019, respectively. Changes in the fair value of net investment hedges are recognized in the Foreign currency translation component of Other comprehensive income (OCI). All of the Company's derivative assets and liabilities measured at fair value are classified as Level 2 within the fair value hierarchy.
Amounts in millions of dollars unless otherwise specified.
Before tax gains/(losses) on our financial instruments in hedging relationships are categorized as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of Gain/(Loss) Recognized in OCI on Derivatives
|
|
|
|
|
|
|
|
|
Three Months Ended March 31
|
|
|
|
Nine Months Ended March 31
|
|
|
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS (1) (2)
|
|
|
|
|
|
|
|
|
Foreign exchange contracts
|
$
|
83
|
|
|
$
|
34
|
|
|
$
|
114
|
|
|
$
|
53
|
|
(1)For the derivatives in net investment hedging relationships, the amount of gain/(loss) excluded from effectiveness testing, which was recognized in earnings, was $17 and $17 for the three months ended March 31, 2020 and 2019, respectively. The amount of gain/(loss) excluded from effectiveness testing was $57 and $44 for the nine months ended March 31, 2020 and 2019, respectively.
(2)In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The amount of gain/(loss) recognized in Accumulated other comprehensive income/(loss) (AOCI) for such instruments was $306 and $226 for the three months ended March 31, 2020 and 2019, respectively. The amount of gain/(loss) recognized in AOCI for such instruments was $487 and $467 for the nine months ended March 31, 2020 and 2019, respectively.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of Gain/(Loss) Recognized in Earnings
|
|
|
|
|
|
|
|
|
Three Months Ended March 31
|
|
|
|
Nine Months Ended March 31
|
|
|
|
|
2020
|
|
2019
|
|
2020
|
|
2019
|
|
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
|
|
|
|
|
|
|
|
|
Interest rate contracts
|
$
|
109
|
|
|
$
|
21
|
|
|
$
|
56
|
|
|
$
|
39
|
|
|
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
|
|
|
|
|
|
|
|
|
Foreign currency contracts
|
$
|
(148)
|
|
|
$
|
75
|
|
|
$
|
(160)
|
|
|
$
|
68
|
|
The gain/(loss) on the derivatives in fair value hedging relationships is fully offset by the mark-to-market impact of the related exposure. These are both recognized in the Consolidated Statements of Earnings in Interest expense. The gain/(loss) on derivatives not designated as hedging instruments is substantially offset by the currency mark-to-market of the related exposure. These are both recognized in the Consolidated Statements of Earnings in Selling, general and administrative expense (SG&A).
8. Accumulated Other Comprehensive Income/(Loss)
The table below presents the changes in AOCI, including the reclassifications out of AOCI by component:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investment Securities
|
|
Pension and Other Retiree Benefits
|
|
Foreign Currency Translation
|
|
Total AOCI
|
|
Balance at June 30, 2019
|
$
|
11
|
|
|
$
|
(4,198)
|
|
|
$
|
(10,749)
|
|
|
$
|
(14,936)
|
|
|
OCI before reclassifications (1)
|
(10)
|
|
|
104
|
|
|
(1,312)
|
|
|
(1,218)
|
|
|
Amounts reclassified from AOCI into the Consolidated Statements of Earnings (2)
|
(2)
|
|
|
223
|
|
|
—
|
|
|
221
|
|
|
Net current period OCI
|
(12)
|
|
|
327
|
|
|
(1,312)
|
|
|
(997)
|
|
|
Less: Other comprehensive income/(loss) attributable to non-controlling interests
|
—
|
|
|
—
|
|
|
(17)
|
|
|
(17)
|
|
|
Balance at March 31, 2020
|
$
|
(1)
|
|
|
$
|
(3,871)
|
|
|
$
|
(12,044)
|
|
|
$
|
(15,916)
|
|
(1)Net of tax expense/(benefit) of $(2), $51 and $141 for gains/losses on investment securities, pension and other retiree benefit items and foreign currency translation, respectively.
(2)Net of tax expense/(benefit) of $0, $66 and $0 for gains/losses on investment securities, pension and other retiree benefit items and foreign currency translation, respectively.
The below provides additional details on amounts reclassified from AOCI into the Consolidated Statements of Earnings:
•Investment securities: amounts reclassified from AOCI into Other non-operating income, net.
•Pension and other retiree benefits: amounts reclassified from AOCI into Other non-operating income, net and included in the computation of net periodic postretirement costs.
Amounts in millions of dollars unless otherwise specified.
9. Restructuring Program
The Company has historically incurred an ongoing annual level of restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization. Before-tax costs incurred under the ongoing program have generally ranged from $250 to $500 annually.
In fiscal 2017 the Company announced specific elements of a multi-year productivity and cost savings plan to further reduce costs in the areas of supply chain, certain marketing activities and overhead expenses. This program is expected to result in incremental targeted enrollment reductions, along with further optimization of the supply chain and other manufacturing processes.
Restructuring costs incurred consist primarily of costs to separate employees, asset-related costs to exit facilities and other costs. For the three and nine month period ended March 31, 2020, the Company incurred total restructuring charges of $222 and $420, respectively. Of these charges incurred, approximately $198 and $331 were recorded in Cost of products sold and approximately $21 and $80 were recorded in SG&A, respectively. The remainder of these charges were recorded in Other non-operating income, net. The following table presents restructuring activity for the nine months ended March 31, 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reserve Balance
|
|
Charges Previously Reported (Six Months Ended December 31, 2019)
|
|
Charges for the Three Months Ended March 31, 2020
|
|
Nine Months Ended March 31, 2020
|
|
|
|
Reserve Balance
|
|
|
June 30, 2019
|
|
|
|
|
|
Cash Spent
|
|
Charges Against Assets
|
|
March 31, 2020
|
|
Separations
|
$
|
280
|
|
|
$
|
81
|
|
|
$
|
41
|
|
|
$
|
(170)
|
|
|
$
|
—
|
|
|
$
|
232
|
|
|
Asset-related costs
|
—
|
|
|
73
|
|
|
148
|
|
|
—
|
|
|
(221)
|
|
|
—
|
|
|
Other costs
|
188
|
|
|
44
|
|
|
33
|
|
|
(107)
|
|
|
—
|
|
|
158
|
|
|
Total
|
$
|
468
|
|
|
$
|
198
|
|
|
$
|
222
|
|
|
$
|
(277)
|
|
|
$
|
(221)
|
|
|
$
|
390
|
|
Separation Costs
Employee separation charges for the three and nine month period ended March 31, 2020 relate to severance packages for approximately 350 and 720 employees, respectively. The packages were primarily voluntary and the amounts were calculated based on salary levels and past service periods. Severance costs related to voluntary separations are generally charged to earnings when the employee accepts the offer.
Asset-Related Costs
Asset-related costs consist of both asset write-downs and accelerated depreciation. Asset write-downs relate to the establishment of a new fair value basis for assets held-for-sale or disposal. These assets were written down to the lower of their current carrying basis or amounts expected to be realized upon disposal, less minor disposal costs. Charges for accelerated depreciation relate to long-lived assets that will be taken out of service prior to the end of their normal service period. These assets relate primarily to manufacturing consolidations and technology standardizations. The asset-related charges will not have a significant impact on future depreciation charges.
Other Costs
Other restructuring-type charges are incurred as a direct result of the restructuring program. Such charges primarily include asset removal and termination of contracts related to supply chain optimization.
Consistent with our historical policies for ongoing restructuring-type activities, the restructuring program charges are funded by and included within Corporate for both management and segment reporting. Accordingly, all of the charges under the program are included within the Corporate reportable segment. However, for informative purposes, the following table summarizes the total restructuring costs related to our reportable segments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2020
|
|
Nine Months Ended March 31, 2020
|
|
Beauty
|
$
|
16
|
|
|
$
|
29
|
|
|
Grooming
|
20
|
|
|
52
|
|
|
Health Care
|
65
|
|
|
89
|
|
|
Fabric & Home Care
|
6
|
|
|
17
|
|
|
Baby, Feminine & Family Care
|
63
|
|
|
92
|
|
|
Corporate (1)
|
52
|
|
|
141
|
|
|
Total Company
|
$
|
222
|
|
|
$
|
420
|
|
(1)Corporate includes costs related to allocated overheads, including charges related to our Market Operations, Global Business Services and Corporate Functions activities.
Amounts in millions of dollars unless otherwise specified.
10. Leases
The Company determines whether a contract contains a lease at the inception of a contract by determining if the contract conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. We lease certain real estate, machinery, equipment, vehicles and office equipment for varying periods. Many of these leases include an option to either renew or terminate the lease. For purposes of calculating lease liabilities, these options are included within the lease term when it has become reasonably certain that the Company will exercise such options. The incremental borrowing rate utilized to calculate our lease liabilities is based on the information available at commencement date, as most of the leases do not provide an implicit borrowing rate. The Company does not have any material financing lease or sublease activities.
The Company incurred lease expense for operating leases of $82 and $255 for the three and nine months ended March 31, 2020, respectively. Total cash paid related to leases during the three and nine months ended March 31, 2020 was $60 and $205, respectively, including amounts expensed and amounts capitalized. Short-term leases, defined as leases with initial terms of 12 months or less, are not reflected on the Consolidated Balance Sheets. Lease expense for such short-term leases is not material. The most significant assets in our leasing portfolio relate to real estate and vehicles. For purposes of calculating lease liabilities for such leases, we have combined lease and non-lease components.
The right-of-use assets obtained in exchange for new lease liabilities were $42 and $70 for the three and nine months ended March 31, 2020, respectively.
Supplemental balance sheet and other information related to leases is as follows:
|
|
|
|
|
|
|
|
|
March 31, 2020
|
|
Operating leases:
|
|
|
Other noncurrent assets
|
$
|
855
|
|
|
|
|
|
Accrued and other liabilities
|
245
|
|
|
Other noncurrent liabilities
|
645
|
|
|
Total operating lease liabilities
|
$
|
890
|
|
|
|
|
|
Weighted average remaining lease term:
|
|
|
Operating leases
|
6.4 years
|
|
|
|
|
Weighted average discount rate:
|
|
|
Operating leases
|
4.4
|
%
|
At March 31, 2020, future payments of operating lease liabilities were as follows:
|
|
|
|
|
|
|
|
|
Operating Leases
|
|
|
March 31, 2020
|
|
1 year
|
$
|
245
|
|
|
2 years
|
193
|
|
|
3 years
|
159
|
|
|
4 years
|
134
|
|
|
5 years
|
93
|
|
|
Over 5 years
|
199
|
|
|
Total lease payments
|
1,023
|
|
|
Less: Interest
|
(133)
|
|
|
Present value of lease liabilities
|
$
|
890
|
|
Amounts in millions of dollars unless otherwise specified.
As of June 30, 2019, minimum lease payments under non-cancelable operating leases by fiscal year were expected to be:
|
|
|
|
|
|
|
|
|
Operating Leases
|
|
|
June 30, 2019
|
|
2020
|
$
|
263
|
|
|
2021
|
209
|
|
|
2022
|
165
|
|
|
2023
|
141
|
|
|
2024
|
121
|
|
|
After 2024
|
244
|
|
|
Total lease payments
|
$
|
1,143
|
|
11. Commitments and Contingencies
Litigation
We are subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust and trade regulation, product liability, advertising, contracts, environmental, patent and trademark matters, labor and employment matters and tax. While considerable uncertainty exists, in the opinion of management and our counsel, the ultimate resolution of the various lawsuits and claims will not materially affect our financial position, results of operations or cash flows.
We are also subject to contingencies pursuant to environmental laws and regulations that in the future may require us to take action to correct the effects on the environment of prior manufacturing and waste disposal practices. Based on currently available information, we do not believe the ultimate resolution of environmental remediation will materially affect our financial position, results of operations or cash flows.
Income Tax Uncertainties
The Company is present in approximately 70 countries and over 150 taxable jurisdictions and, at any point in time, has 40–50 jurisdictional audits underway at various stages of completion. We evaluate our tax positions and establish liabilities for uncertain tax positions that may be challenged by local authorities and may not be fully sustained, despite our belief that the underlying tax positions are fully supportable. Uncertain tax positions are reviewed on an ongoing basis and are adjusted in light of changing facts and circumstances, including progress of tax audits, developments in case law and closing of statutes of limitations. Such adjustments are reflected in the tax provision as appropriate. We have tax years open ranging from 2008 and forward. We are generally not able to reliably estimate the ultimate settlement amounts until the close of the audit. Based on information currently available, we anticipate that over the next 12 month period, audit activity could be completed related to uncertain tax positions in multiple jurisdictions for which we have accrued existing liabilities of approximately $50, including interest and penalties.
Additional information on the Commitments and Contingencies of the Company can be found in our Annual Report on Form 10-K for the year ended June 30, 2019.
Amounts in millions of dollars unless otherwise specified.
12. Merck Acquisition
On November 30, 2018, we completed our acquisition of the OTC healthcare business of Merck KGaA (Merck OTC) for $3.7 billion (based on exchange rates at the time of closing) in an all-cash transaction. This business primarily sells OTC consumer healthcare products, mainly in Europe, Latin America and Asia markets. The results of Merck OTC, which are not material to the Company, are reported in our consolidated financial statements beginning December 1, 2018.
During the quarter ended December 31, 2019, we completed the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation is based on the final determination of fair values of the assets and liabilities acquired. The following table presents the allocation of purchase price related to the Merck OTC business as of the date of the acquisition:
|
|
|
|
|
|
|
|
Amounts in millions
|
November 30, 2018
|
|
Current assets
|
$
|
421
|
|
|
Property, plant and equipment
|
119
|
|
|
Intangible assets
|
2,134
|
|
|
Goodwill
|
2,083
|
|
|
Other non-current assets
|
209
|
|
|
Total assets acquired
|
$
|
4,966
|
|
|
|
|
|
Current liabilities
|
$
|
232
|
|
|
Deferred income taxes
|
763
|
|
|
Non-current liabilities
|
94
|
|
|
Total liabilities acquired
|
$
|
1,089
|
|
|
|
|
|
Noncontrolling interest (1)
|
$
|
169
|
|
|
|
|
|
Net assets acquired
|
$
|
3,708
|
|
(1)Represents a 48% minority ownership interest in the Merck India company.
The acquisition resulted in $2.1 billion in goodwill, of which approximately $180 million is expected to be deductible for tax purposes. All of this goodwill was allocated to the Health Care reportable segment.
The fair value of Merck OTC’s identifiable intangible assets is $2.1 billion. The allocation of identifiable intangible assets and their average useful lives is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts in millions
|
Estimated Fair Value
|
|
Avg Remaining
Useful Life
|
|
Intangible assets with determinable lives
|
|
|
|
|
Brands
|
$
|
701
|
|
|
14
|
|
Patents and technology
|
162
|
|
|
10
|
|
Customer relationships
|
325
|
|
|
20
|
|
Total
|
$
|
1,188
|
|
|
15
|
|
|
|
|
|
|
Intangible assets with indefinite lives
|
|
|
|
|
Brands
|
946
|
|
|
|
|
Total intangible assets
|
$
|
2,134
|
|
|
|
The majority of the acquired intangible assets relate to brand intangibles. Our assessment as to brand intangibles that have an indefinite life and those that have a definite life was based on a number of factors, including competitive environment, market share, brand history, product life cycles, operating plan and the macroeconomic environment of the countries in which the brands are sold. The indefinite-lived brand intangibles include Neurobion and Dolo Neurobion. The definite-lived brand intangibles primarily include regional or local brands. The definite-lived brand intangibles have estimated lives ranging from 10 to 20 years. The technology intangibles are related to R&D and manufacturing know-how. The customer relationships intangibles are related to Merck OTC’s relationships with health care professionals, retailers and distributors.
Amounts in millions of dollars unless otherwise specified.
|
|
|
|
|
|
|
|
Item 2.
|
Management's Discussion and Analysis of Financial Condition and Results of Operations
|
Forward-Looking Statements
Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may appear throughout this report, including, without limitation, the following sections: “Management's Discussion and Analysis,” “Risk Factors,” and "Notes 4 and 11 to the Consolidated Financial Statements." These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and uncertainties that may cause results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether because of new information, future events or otherwise, except to the extent required by law.
Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial risks, including foreign currency fluctuations, currency exchange or pricing controls and localized volatility; (2) the ability to successfully manage local, regional or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow the Company to effect the expected share repurchases and dividend payments; (3) the ability to manage disruptions in credit markets or changes to our credit rating; (4) the ability to maintain key manufacturing and supply arrangements (including execution of supply chain optimizations and sole supplier and sole manufacturing plant arrangements) and to manage disruption of business due to factors outside of our control, such as natural disasters, acts of war or terrorism, or disease outbreaks; (5) the ability to successfully manage cost fluctuations and pressures, including prices of commodities and raw materials, and costs of labor, transportation, energy, pension and healthcare; (6) the ability to stay on the leading edge of innovation, obtain necessary intellectual property protections and successfully respond to changing consumer habits and technological advances attained by, and patents granted to, competitors; (7) the ability to compete with our local and global competitors in new and existing sales channels, including by successfully responding to competitive factors such as prices, promotional incentives and trade terms for products; (8) the ability to manage and maintain key customer relationships; (9) the ability to protect our reputation and brand equity by successfully managing real or perceived issues, including concerns about safety, quality, ingredients, efficacy or similar matters that may arise; (10) the ability to successfully manage the financial, legal, reputational and operational risk associated with third-party relationships, such as our suppliers, contract manufacturers, distributors, contractors and external business partners; (11) the ability to rely on and maintain key company and third party information technology systems, networks and services, and maintain the security and functionality of such systems, networks and services and the data contained therein; (12) the ability to successfully manage uncertainties related to changing political conditions (including the United Kingdom’s exit from the European Union) and potential implications such as exchange rate fluctuations and market contraction; (13) the ability to successfully manage regulatory and legal requirements and matters (including, without limitation, those laws and regulations involving product liability, product and packaging composition, intellectual property, labor and employment, antitrust, data protection, tax, environmental, and accounting and financial reporting) and to resolve pending matters within current estimates; (14) the ability to manage changes in applicable tax laws and regulations including maintaining our intended tax treatment of divestiture transactions; (15) the ability to successfully manage our ongoing acquisition, divestiture and joint venture activities, in each case to achieve the Company’s overall business strategy and financial objectives, without impacting the delivery of base business objectives; (16) the ability to successfully achieve productivity improvements and cost savings and manage ongoing organizational changes, while successfully identifying, developing and retaining key employees, including in key growth markets where the availability of skilled or experienced employees may be limited; and (17) the ability to successfully manage the demand, supply, and operational challenges associated with a disease outbreak, including epidemics, pandemics, or similar widespread public health concerns (including the novel coronavirus, COVID-19, outbreak). A detailed discussion of risks and uncertainties that could cause actual results and events to differ materially from those projected herein, is included in the section titled "Economic Conditions and Uncertainties" and the section titled "Risk Factors" (Part II, Item 1A) of this Form 10-Q.
The purpose of Management's Discussion and Analysis (MD&A) is to provide an understanding of Procter & Gamble's financial condition, results of operations and cash flows by focusing on changes in certain key measures from year to year. The MD&A is provided as a supplement to, and should be read in conjunction with, our Consolidated Financial Statements and accompanying notes.
The MD&A is organized in the following sections:
•Overview
•Summary of Results – Nine Months Ended March 31, 2020
•Economic Conditions and Uncertainties
•Results of Operations – Three and Nine Months Ended March 31, 2020
•Business Segment Discussion – Three and Nine Months Ended March 31, 2020
•Liquidity and Capital Resources
•Reconciliation of Measures Not Defined by U.S. GAAP
Throughout the MD&A, we refer to measures used by management to evaluate performance, including unit volume growth, net sales and net earnings. We also refer to a number of financial measures that are not defined under accounting principles generally accepted in the United States of America (U.S. GAAP), consisting of organic sales growth, core net earnings per share (Core EPS), adjusted free cash flow and adjusted free cash flow productivity. The explanation at the end of the MD&A provides the definition of these non-GAAP measures, details on the use and the derivation of these measures, as well as reconciliations to the most directly comparable U.S. GAAP measures.
Management also uses certain market share and market consumption estimates to evaluate performance relative to competition despite some limitations on the availability and comparability of share and consumption information. References to market share and market consumption in the MD&A are based on a combination of vendor purchased traditional brick-and-mortar and online data in key markets as well as internal estimates. All market share references represent the percentage of sales of our products in dollar terms on a constant currency basis, relative to all product sales in the category. The Company measures fiscal year to date market shares through the most recent period for which market share data is available, which typically reflects a lag time of one or two months as compared to the end of the reporting period. Management also uses unit volume growth to evaluate and explain drivers of changes in net sales. Organic volume growth reflects year-over-year changes in unit volume excluding the impacts of acquisitions and divestitures and certain one-time items if applicable and is used to explain changes in organic sales.
OVERVIEW
P&G is a global leader in the fast-moving consumer goods industry, focused on providing branded consumer packaged goods of superior quality and value to our consumers around the world. Our products are sold in more than 180 countries and territories, primarily through mass merchandisers, e-commerce, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, baby stores, specialty beauty stores, high-frequency stores and pharmacies. We also sell direct to consumers. We have on-the-ground operations in approximately 70 countries.
Our market environment is highly competitive with global, regional and local competitors. In many of the markets and industry segments in which we sell our products, we compete against other branded products as well as retailers' private-label brands. Additionally, many of the product segments in which we compete are differentiated by price tiers (referred to as super-premium, premium, mid-tier and value-tier products). We believe we are well positioned in the industry segments and markets in which we operate, often holding a leadership or significant market share position.
The table below provides detail on our reportable segments, including the product categories and brand composition within each segment.
|
|
|
|
|
|
|
|
|
|
|
Reportable Segments
|
Product Categories (Sub-Categories)
|
Major Brands
|
|
Beauty
|
Hair Care (Conditioner, Shampoo, Styling Aids, Treatments)
|
Head & Shoulders, Herbal Essences, Pantene, Rejoice
|
|
|
Skin and Personal Care (Antiperspirant and Deodorant, Personal Cleansing, Skin Care)
|
Olay, Old Spice, Safeguard, SK-II, Secret
|
|
Grooming
|
Grooming (1) (Shave Care - Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Shave Care; Appliances)
|
Braun, Gillette, Venus
|
|
Health Care
|
Oral Care (Toothbrushes, Toothpaste, Other Oral Care)
|
Crest, Oral-B
|
|
|
Personal Health Care (Gastrointestinal, Rapid Diagnostics, Respiratory, Vitamins/Minerals/Supplements, Pain Relief, Other Personal Health Care)
|
Metamucil, Neurobion, Pepto Bismol, Vicks
|
|
Fabric & Home Care
|
Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents)
|
Ariel, Downy, Gain, Tide
|
|
|
Home Care (Air Care, Dish Care, P&G Professional, Surface Care)
|
Cascade, Dawn, Fairy, Febreze, Mr. Clean, Swiffer
|
|
Baby, Feminine & Family Care
|
Baby Care (Baby Wipes, Taped Diapers and Pants)
|
Luvs, Pampers
|
|
|
Feminine Care (Adult Incontinence, Feminine Care)
|
Always, Always Discreet, Tampax
|
|
|
Family Care (Paper Towels, Tissues, Toilet Paper)
|
Bounty, Charmin, Puffs
|
(1)The Grooming product category is comprised of the Shave Care and Appliances operating segments.
The following table provides the percentage of net sales and net earnings by reportable business segment for the three and nine months ended March 31, 2020 (excluding net sales and net earnings in Corporate):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2020
|
|
|
|
Nine Months Ended March 31, 2020
|
|
|
|
|
Net Sales
|
|
Net Earnings
|
|
Net Sales
|
|
Net Earnings
|
|
Beauty
|
18%
|
|
|
15%
|
|
|
19%
|
|
|
22%
|
|
|
Grooming
|
8%
|
|
|
9%
|
|
|
9%
|
|
|
10%
|
|
|
Health Care
|
13%
|
|
|
14%
|
|
|
13%
|
|
|
14%
|
|
|
Fabric & Home Care
|
34%
|
|
|
33%
|
|
|
33%
|
|
|
29%
|
|
|
Baby, Feminine & Family Care
|
27%
|
|
|
29%
|
|
|
26%
|
|
|
25%
|
|
|
Total Company
|
100%
|
|
|
100%
|
|
|
100%
|
|
|
100%
|
|
SUMMARY OF RESULTS
Following are highlights of results for the nine months ended March 31, 2020 versus the nine months ended March 31, 2019:
•Net sales increased 5% to $53.3 billion, driven by a double digit increase in Health Care, mid-single digits increases in Beauty and Fabric & Home Care and a low single digits increase in Baby, Feminine & Family Care, partially offset by a low single digits decrease in Grooming. Organic sales, which exclude the impacts of acquisitions and divestitures and foreign exchange, increased 6%, driven by high single digits increase in Health Care and Fabric & Home Care, mid-single digits increases in Beauty and Baby, Feminine & Family Care and low single digits increases in Grooming.
•Unit volume increased 5% , with organic volume up 4%. Volume increased double digits in Health Care, mid-single digits in Fabric & Home Care and low single digits in Beauty and in Baby, Feminine & Family Care. Grooming volume was unchanged. Excluding the impacts of the Merck OTC acquisition, organic volume increased high single digits in Health Care.
•Net earnings were $10.3 billion, an increase of $1.1 billion or 12% versus the prior year period due to the increase in net sales, an increase in operating margin and a reduction in the current period income tax rate, partially offset by the base period gain on the dissolution of the PGT Healthcare partnership.
•Net earnings attributable to Procter & Gamble increased $1.1 billion or 12% versus the prior year period to $10.2 billion .
•Diluted net earnings per share increased 12% to $3.89 due primarily to the increase in net earnings.
•Core net earnings attributable to Procter & Gamble, which represents net earnings excluding incremental restructuring charges in both periods and the base period gain on the dissolution of the PGT Healthcare partnership, increased 16% to $10.4 billion. Core net earnings per share increased 16% to $3.96 due primarily to the increase in Core net earnings.
•Operating cash flow was $12.6 billion. Adjusted free cash flow, which is operating cash flow less capital expenditures and certain other impacts, was $10.4 billion. Adjusted free cash flow productivity was 101%.
ECONOMIC CONDITIONS AND UNCERTAINTIES
Global Economic Conditions. Our products are sold in numerous countries across North America, Europe, Latin America, Asia and Africa with more than half our sales generated outside the United States. As such, we are exposed to and impacted by global macroeconomic factors, U.S. and foreign government policies and foreign exchange fluctuations. Current global economic conditions are highly volatile due to the COVID-19 pandemic, resulting in both market size contractions in certain countries due to economic slowdowns and government restrictions on movement, as well as market size increases in certain countries due to pantry loading and increased consumption of household cleaning and personal health and hygiene products by consumers. Other macroeconomic factors also remain dynamic, and any causes of market size contraction, such as reduced GDP in commodity-dependent economies, greater political unrest or instability in the Middle East, Central & Eastern Europe, certain Latin American markets, the Hong Kong market in Greater China and the Korean peninsula, economic uncertainty related to the United Kingdom's exit from the European Union, and overall economic slowdowns, could reduce our sales or erode our operating margin, in either case reducing our earnings.
Changes in Costs. Our costs are subject to fluctuations, particularly due to changes in commodity prices, transportation costs and our own productivity efforts. We have significant exposures to certain commodities, in particular, certain oil-derived materials like resins and paper-based materials like pulp, and volatility in the market price of these commodity input materials has a direct impact on our costs. Disruptions in our manufacturing, supply and distribution operations due to the COVID-19 pandemic may also impact our costs. If we are unable to manage these impacts through pricing actions, cost savings projects and sourcing decisions, as well as through consistent productivity improvements, it may adversely impact our gross margin, operating margin and net earnings. Sales could also be adversely impacted following pricing actions if there is a negative impact on consumption of our products. We strive to implement, achieve and sustain cost improvement plans, including outsourcing projects, supply chain optimization and general overhead and workforce optimization. As discussed later in this MD&A, in 2012 we initiated overhead and supply chain cost improvement projects. In fiscal 2017, we communicated specific elements of an additional multi-year cost reduction program which is resulting in targeted enrollment reductions and other savings. If we are not successful in executing and sustaining these changes, there could be a negative impact on our operating margin and net earnings.
Foreign Exchange. We have both translation and transaction exposure to the fluctuation of exchange rates. Translation exposures relate to exchange rate impacts of measuring income statements of foreign subsidiaries that do not use the U.S. dollar as their functional currency. Transaction exposures relate to 1) the impact from input costs that are denominated in a currency other than the local reporting currency and 2) the revaluation of transaction-related working capital balances denominated in currencies other than the functional currency. In four of the past five fiscal years, as well as the current year, the U.S. dollar has strengthened versus a number of foreign currencies, leading to lower sales and earnings from these foreign exchange impacts. Certain countries experiencing significant exchange rate fluctuations, like Argentina, Brazil, Greater China, Turkey and the United Kingdom have previously had, and could in the future have, a significant impact on our sales, costs and earnings. Increased pricing in response to certain fluctuations in foreign currency exchange rates may offset portions of the currency impacts but could also have a negative impact on consumption of our products, which would affect our sales and profits.
Government Policies. Our net earnings could be affected by changes in U.S. or foreign government tax policies, for example, the U.S. Tax Act enacted in December 2017, and the current work being led by the OECD for the G20 focused on "Addressing the Challenges of the Digitalization of the Economy." The breadth of this project extends beyond pure digital businesses and is likely to impact all multinational businesses by redefining jurisdictional taxing rights. Further, our earnings and sales may be impacted by U.S. and foreign government policies to manage the COVID-19 pandemic, such as movement restrictions or site closures. Additionally, we attempt to carefully manage our debt, currency and other exposures in certain countries with currency exchange, import authorization and pricing controls, such as Nigeria, Algeria, Egypt, Argentina and Turkey. Further, our earnings and sales could be affected by changes to international trade agreements in North America and elsewhere, including increases of import tariffs, both currently effective and potential future changes. Changes in government policies in these areas might cause an increase or decrease in our sales, operating margin and net earnings.
For information on risk factors that could impact our results, please refer to “Risk Factors” in Part II, Item 1A of this Form 10-Q.
COVID-19 Pandemic disclosures
The Company’s priorities during the COVID-19 pandemic are protecting the health and safety of our employees; maximizing the availability of products that help consumers with their health, hygiene and cleaning needs; and the use of our employees’
talents and our resources to help society meet and overcome the current challenges. Because the Company sells products that are essential to the daily lives of consumers, the COVID-19 pandemic has not had a material net impact to our consolidated operating results in the current quarter. However, the pandemic has had offsetting impacts during the period. For example, during the quarter ended March 31, 2020 we experienced a significant increase in demand and consumption of certain of our product categories in certain markets (the health, hygiene and cleaning products, and primarily in North America and Europe) caused in part by changing consumer habits and pantry stocking, contributing to increases in net sales. At the same time, we experienced declines in Greater China, Japan, and in certain channels, including travel retail, due to the economic slowdown and restricted consumer movements, as well as in certain of our beauty and grooming products. In the future, the pandemic may cause reduced demand for our products if it results in a recessionary global economic environment. It could also lead to volatility in consumer access to our products due to government actions impacting our ability to produce and ship products or impacting consumers’ movements and access to our products. We believe that over the long term, there will continue to be strong demand for categories in which we operate, particularly our products that deliver essential health, hygiene and cleaning benefits. However, the timing and extent of demand recovery in markets such as Greater China and Japan, the resumption of international travel, the timing and impact of potential consumer pantry destocking in markets including North America and Europe, and product demand trends caused by future economic trends are unclear. Accordingly, there may be heightened volatility in net sales and resulting earnings during and subsequent to the duration of the pandemic. Our retail customers are also being impacted by the pandemic. Their success in addressing the issues and maintaining their operations could impact consumer access to, and as a result, sales of our products.
Our ability to continue to operate without any significant negative impacts will in part depend on our ability to protect our employees and our supply chain. The Company has endeavored to follow recommended actions of government and health authorities to protect our employees world-wide, with particular measures in place for those working in our plants and distribution facilities. We have also worked closely with local and national officials to keep our manufacturing facilities open due to the essential nature of our products. For the three months ended March 31, 2020, we were able to broadly maintain our operations. We intend to continue to work with government authorities and implement our employee safety measures to ensure that we are able to continue manufacturing and distributing our products during the pandemic. However, uncertainty resulting from the pandemic could result in an unforeseen disruption to our supply chain (for example a closure of a key manufacturing or distribution facility or the inability of a key supplier or transportation supplier to source and transport materials) that could impact our operations.
Because the pandemic has not materially impacted our operations or demand for our products, it has also not negatively impacted the Company’s liquidity position. We continue to generate operating cash flows to meet our short-term liquidity needs, and we expect to maintain access to the capital markets enabled by our strong short- and long-term debt ratings. We have also not observed any material impairments of our assets or a significant change in the fair value of assets due to the COVID-19 pandemic.
For additional information on risk factors that could impact our results, please refer to “Risk Factors” in Part II, Item 1A of this Form 10-Q.
RESULTS OF OPERATIONS – Three Months Ended March 31, 2020
The following discussion provides a review of results for the three months ended March 31, 2020 versus the three months ended March 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31
|
|
|
|
|
|
Amounts in millions, except per share amounts
|
2020
|
|
2019
|
|
% Chg
|
|
Net sales
|
$17,214
|
|
|
$16,462
|
|
|
5%
|
|
|
Operating income
|
3,453
|
|
|
3,229
|
|
|
7%
|
|
|
Net earnings
|
2,957
|
|
|
2,776
|
|
|
7%
|
|
|
Net earnings attributable to Procter & Gamble
|
2,917
|
|
|
2,745
|
|
|
6%
|
|
|
Diluted net earnings per common share
|
1.12
|
|
|
1.04
|
|
|
8%
|
|
|
Core net earnings per common share
|
1.17
|
|
|
1.06
|
|
|
10%
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31
|
|
|
|
|
|
COMPARISONS AS A PERCENTAGE OF NET SALES
|
2020
|
|
2019
|
|
Basis Pt Chg
|
|
Gross margin
|
49.4%
|
|
|
48.8%
|
|
|
60
|
|
|
Selling, general & administrative expense
|
29.3%
|
|
|
29.2%
|
|
|
10
|
|
|
Operating income
|
20.1%
|
|
|
19.6%
|
|
|
50
|
|
|
Earnings before income taxes
|
20.3%
|
|
|
19.9%
|
|
|
40
|
|
|
Net earnings
|
17.2%
|
|
|
16.9%
|
|
|
30
|
|
|
Net earnings attributable to Procter & Gamble
|
16.9%
|
|
|
16.7%
|
|
|
20
|
|
Net Sales
Net sales for the quarter increased 5% to $17.2 billion including a 2% negative impact from foreign exchange. Unit volume increased 6%. Excluding the impacts of acquisitions and divestitures, organic volume also increased 6%. Increased pricing had a 1% positive impact to net sales. Mix had no impact to net sales. Volume increased high single digits in Heath Care, Fabric & Home Care and in Baby, Feminine & Family Care, and increased low single digits in Beauty. Grooming volume was unchanged. On a regional basis, volume increased double digits in North America and high single digits in Europe driven by innovation, increased demand and market growth, particularly in household cleaning and personal health and hygiene products due in part to the COVID-19 pandemic. Volume increased mid-single digits in Asia Pacific and Latin America. These increases were partially offset by a double digits volume decrease in Greater China due to market contraction driven by economic slowdown resulting from COVD-19 and a low single digits decrease in India, Middle East and Africa (IMEA). Organic sales increased 6% on a 6% increase in organic volume.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales Change Drivers 2020 vs. 2019 (Three Months Ended March 31) (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume with Acquisitions & Divestitures
|
|
Volume Excluding Acquisitions & Divestitures
|
|
Foreign Exchange
|
|
Price
|
|
Mix
|
|
Other (2)
|
|
Net Sales Growth
|
|
Beauty
|
1%
|
|
|
1%
|
|
|
(2)%
|
|
|
2%
|
|
|
(2)%
|
|
|
—%
|
|
|
(1)%
|
|
|
Grooming
|
—%
|
|
|
—%
|
|
|
(3)%
|
|
|
2%
|
|
|
(2)%
|
|
|
—%
|
|
|
(3)%
|
|
|
Health Care
|
7%
|
|
|
7%
|
|
|
(2)%
|
|
|
1%
|
|
|
1%
|
|
|
—%
|
|
|
7%
|
|
|
Fabric & Home Care
|
8%
|
|
|
8%
|
|
|
(1)%
|
|
|
—%
|
|
|
1%
|
|
|
—%
|
|
|
8%
|
|
|
Baby, Feminine & Family Care
|
7%
|
|
|
7%
|
|
|
(1)%
|
|
|
—%
|
|
|
—%
|
|
|
—%
|
|
|
6%
|
|
|
Total Company
|
6%
|
|
|
6%
|
|
|
(2)%
|
|
|
1%
|
|
|
—%
|
|
|
—%
|
|
|
5%
|
|
(1)Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
(2)Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.
Operating Costs
Gross margin increased 60 basis points to 49.4% of net sales for the quarter. Gross margin benefited from:
•170 basis points of gross manufacturing cost savings projects (150 basis points net of product and packaging reinvestments),
•100 basis points of lower commodity costs, and
•40 basis points of positive pricing impacts
These benefits were partially offset by a 160 basis point decline from unfavorable mix (due to the disproportionate growth of Fabric & Home Care and Baby, Feminine & Family Care segments which have lower than company average margins, as well as mix within segments due to the growth of lower margin product forms and large sizes in certain categories), a 60 basis-point decline from higher restructuring costs and a 10 basis-point decline from unfavorable foreign exchange.
Total SG&A spending increased 5% to $5.0 billion primarily due to increases in marketing spending and other operating costs. SG&A as a percentage of net sales increased 10 basis points to 29.3% due to an increase in marketing spending and other net operating costs as a percentage of net sales, partially offset by a reduction in overhead costs as a percentage of net sales. Marketing spending as a percentage of net sales increased 40 basis points as the positive scale impacts of the net sales increase and savings in agency compensation, production costs and advertising spending were more than offset by reinvestments in media. Overhead costs as a percentage of net sales declined 50 basis points due to the positive scale impacts of the net sales increase and productivity savings, partially offset by inflation and other cost increases. Other net operating costs as a percentage of net sales increased 30 basis points primarily due to an increase in foreign exchange transaction charges. Productivity-driven cost savings delivered 70 basis points of benefit to SG&A as a percentage of net sales.
Non-Operating Expenses and Income
Interest expense was $100 million for the quarter, a decrease of $31 million versus the prior year period due to a decrease in average debt balances and a reduction in U.S. interest rates. Interest income was $39 million for the quarter, a $13 million decrease versus the prior year period due to lower average cash and investment securities balances and reduced U.S. interest rates. Other non-operating income was $106 million, a decrease of $22 million due to higher costs on certain postretirement benefit plans in the current period.
Income Taxes
For the three months ended March 31, 2020, the effective tax rate increased 20 basis points versus the prior year period to 15.5%. A 290 basis-point increase from an unfavorable geographic mix of earnings, caused primarily by disproportionately higher sales and earnings in the U.S. was partially offset by:
•a 150 basis-point reduction from a non-recurring tax benefit arising from a simplification of our legal entity structure,
•a 70 basis-point reduction from discrete impacts related to uncertain tax positions (30 basis-point reduction in the current period versus 40 basis-point increase in the prior year period) and
•a 40 basis-point reduction from increased excess tax benefits of share-based compensation (280 basis-point reduction in the current period versus 240 basis-point reduction in the prior year period).
Net Earnings
Operating income increased $224 million, or 7% to $3.5 billion for the quarter, due to the net sales increase and the increase in gross margin, partially offset by the increase in SG&A as a percentage of sales, all of which are described above. Net earnings increased $181 million or 7% to $3 billion due to the increase in operating income. Foreign exchange had a negative impact of approximately $144 million on net earnings for the quarter, including both transactional charges and translational impacts from converting earnings from foreign subsidiaries to U.S. dollars. Net earnings attributable to Procter & Gamble increased $172 million or 6% to $2.9 billion for the quarter. Diluted net earnings per share increased 8% to $1.12. Core net earnings per share increased 10% to $1.17. Core net earnings per share represents diluted net earnings per share, excluding the incremental restructuring charges in both periods related to our productivity and cost savings plans.
RESULTS OF OPERATIONS – Nine Months Ended March 31, 2020
The following discussion provides a review of results for the nine months ended March 31, 2020 versus the nine months ended March 31, 2019.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended March 31
|
|
|
|
|
|
Amounts in millions, except per share amounts
|
2020
|
|
2019
|
|
% Chg
|
|
Net sales
|
$53,252
|
|
|
$50,590
|
|
|
5%
|
|
|
Operating income
|
12,225
|
|
|
10,679
|
|
|
14%
|
|
|
Net earnings
|
10,317
|
|
|
9,203
|
|
|
12%
|
|
|
Net earnings attributable to Procter & Gamble
|
10,227
|
|
|
9,138
|
|
|
12%
|
|
|
Diluted net earnings per common share
|
3.89
|
|
|
3.48
|
|
|
12%
|
|
|
Core net earnings per common share
|
3.96
|
|
|
3.42
|
|
|
16%
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended March 31
|
|
|
|
|
|
COMPARISONS AS A PERCENTAGE OF NET SALES
|
2020
|
|
2019
|
|
Basis Pt Chg
|
|
Gross margin
|
50.6%
|
|
|
48.9%
|
|
|
170
|
|
|
Selling, general & administrative expense
|
27.6%
|
|
|
27.8%
|
|
|
(20)
|
|
|
Operating income
|
23.0%
|
|
|
21.1%
|
|
|
190
|
|
|
Earnings before income taxes
|
23.2%
|
|
|
22.0%
|
|
|
120
|
|
|
Net earnings
|
19.4%
|
|
|
18.2%
|
|
|
120
|
|
|
Net earnings attributable to Procter & Gamble
|
19.2%
|
|
|
18.1%
|
|
|
110
|
|
Net Sales
Net sales for the nine months ended March 31, 2020 increased 5% to $53.3 billion including a 2% negative impact from foreign exchange. Unit volume increased 5%. Excluding the impacts of acquisitions and divestitures, organic volume increased 4%. Increased pricing had a 1% favorable impact to net sales. Mix was a 1% positive impact to net sales, driven primarily by disproportionate organic growth of the Health Care segment and the Skin & Personal Care category, both of which have higher than company average selling prices. Volume increased double digits in Health Care, increased mid-single digits in Fabric & Home Care and increased low single digits in Beauty and in Baby, Feminine & Family Care. Volume was unchanged in Grooming. Excluding the impacts of the Merck OTC acquisition, Health Care organic volume increased high single digits. On a regional basis volume grew mid-single digits in North America, Europe, Asia Pacific and Latin America and grew low single digits in IMEA. Excluding the impact of minor acquisitions and divestitures, organic volume increased low single digits in Latin America. Organic sales increased 6% on a 4% increase in organic volume.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales Change Drivers 2020 vs. 2019 (Nine Months Ended March 31) (1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Volume with Acquisitions & Divestitures
|
|
Volume Excluding Acquisitions & Divestitures
|
|
Foreign Exchange
|
|
Price
|
|
Mix
|
|
Other (2)
|
|
Net Sales Growth
|
|
Beauty
|
3%
|
|
|
3%
|
|
|
(2)%
|
|
|
2%
|
|
|
1%
|
|
|
1%
|
|
|
5%
|
|
|
Grooming
|
—%
|
|
|
—%
|
|
|
(2)%
|
|
|
2%
|
|
|
(1)%
|
|
|
—%
|
|
|
(1)%
|
|
|
Health Care
|
13%
|
|
|
7%
|
|
|
(2)%
|
|
|
1%
|
|
|
1%
|
|
|
—%
|
|
|
13%
|
|
|
Fabric & Home Care
|
6%
|
|
|
6%
|
|
|
(1)%
|
|
|
—%
|
|
|
1%
|
|
|
—%
|
|
|
6%
|
|
|
Baby, Feminine & Family Care
|
3%
|
|
|
3%
|
|
|
(1)%
|
|
|
1%
|
|
|
—%
|
|
|
—%
|
|
|
3%
|
|
|
Total Company
|
5%
|
|
|
4%
|
|
|
(2)%
|
|
|
1%
|
|
|
1%
|
|
|
—%
|
|
|
5%
|
|
(1)Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
(2)Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.
Operating Costs
Gross margin increased 170 basis points to 50.6% of net sales for the nine months ended March 31, 2020. Gross margin benefited from:
•130 basis points of gross manufacturing cost savings projects (110 basis points net of product and packaging reinvestments),
•50 basis points of positive pricing impacts, and
•70 basis points of lower commodity costs
These benefits were partially offset by a 10 basis-point decline from unfavorable foreign exchange and a 50 basis point net decline from unfavorable product mix (primarily mix within segments due to the growth of lower margin product forms and large sizes in certain categories) and other impacts.
Total SG&A spending increased 5% to $14.7 billion for the nine months ended March 31, 2020, primarily due to increases in marketing spending and to a lesser extent overhead costs. SG&A as a percentage of net sales decreased 20 basis points to 27.6% due to a decrease in overhead and other operating costs as a percentage of net sales, partially offset by an increase in marketing spending as a percentage of sales. Marketing spending as a percentage of net sales increased 10 basis points as the positive scale impacts of the net sales increase and savings in agency compensation, production costs and advertising spending, were more than offset by reinvestments in media and other marketing spending. Overhead costs as a percentage of net sales decreased 30 basis points driven by the positive scale impacts of the net sales increase, productivity savings and lower restructuring charges versus the base period, partially offset by inflation, higher incentive compensation costs and other cost increases. Other net operating costs as a percentage of net sales decreased 10 basis points primarily due to gains from legal settlements, partially offset by an increase in foreign exchange transaction charges. Productivity-driven cost savings delivered 80 basis points of benefit to SG&A as a percentage of net sales.
Non-Operating Expenses and Income
Interest expense was $308 million for the nine months ended March 31, 2020, a decrease of $90 million versus the prior year period due to a decrease in average debt balances and a reduction in U.S. interest rates. Interest income was $133 million for the nine months ended March 31, 2020, a decrease of $35 million versus the prior year period due to a decrease in cash and investment securities balances and a reduction in U.S. interest rates. Other non-operating income was $323 million, a decrease of $362 million primarily due to the base period gain from the dissolution of the PGT Healthcare partnership.
Income Taxes
For the nine months ended March 31, 2020, the effective tax rate decreased 70 basis points versus the prior year period to 16.6% due to:
•a 130 basis-point reduction from a non-recurring tax benefit arising from a simplification of our legal entity structure and
•a 40 basis-point reduction from increased excess tax benefits of share-based compensation (a 180 basis-point reduction in the current year versus a 140 basis-point reduction in the prior year).
These reductions are partially offset by:
•a 60 basis-point increase related to the prior year tax impact of the gain on the dissolution of the PGT Healthcare partnership and
•a 30 basis-point increase from unfavorable geographic mix of earnings.
Net Earnings
Operating income increased $1.5 billion, or 14% to $12.2 billion for the nine months ended March 31, 2020, due to the net sales increase, the increase in gross margin and the reduction in SG&A as a percentage of sales, all of which are described above. Net earnings increased $1.1 billion or 12% to $10.3 billion for the fiscal year to date period due to the increase in operating income and the lower tax rates as described above, partially offset by the base period gain on the PGT Healthcare partnership dissolution. Foreign exchange had a negative impact of approximately $234 million on net earnings for the fiscal year to date period, including both transactional charges and translational impacts from converting earnings from foreign subsidiaries to U.S. dollars. Net earnings attributable to Procter & Gamble increased $1.1 billion or 12% to $10.2 billion for the fiscal year to date period. Diluted net earnings per share increased 12% to $3.89. Core net earnings per share increased 16% to $3.96. Core net earnings per share represents diluted net earnings per share excluding the incremental restructuring charges in both periods related to our productivity and cost savings plans and the gain on dissolution of the PGT Healthcare partnership in the base period.
BUSINESS SEGMENT DISCUSSION – Three and Nine Months Ended March 31, 2020
The following discussion provides a review of results by reportable business segment. Analysis of the results for the three and nine month periods ended March 31, 2020 is provided based on a comparison to the same three and nine months periods ended March 31, 2019. The primary financial measures used to evaluate segment performance are net sales and net earnings. The table below provides supplemental information on net sales and net earnings by reportable business segment for the three and nine months ended March 31, 2020 versus the comparable prior year periods (dollar amounts in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales
|
|
% Change Versus Year Ago
|
|
Earnings/(Loss) Before Income Taxes
|
|
% Change Versus Year Ago
|
|
Net Earnings
|
|
% Change Versus Year Ago
|
|
Beauty
|
$
|
3,033
|
|
|
(1)
|
%
|
|
$
|
553
|
|
|
(18)
|
%
|
|
$
|
436
|
|
|
(21)
|
%
|
|
Grooming
|
1,380
|
|
|
(3)
|
%
|
|
305
|
|
|
(7)
|
%
|
|
254
|
|
|
(26)
|
%
|
|
Health Care
|
2,262
|
|
|
7
|
%
|
|
523
|
|
|
13
|
%
|
|
408
|
|
|
14
|
%
|
|
Fabric & Home Care
|
5,826
|
|
|
8
|
%
|
|
1,271
|
|
|
14
|
%
|
|
957
|
|
|
13
|
%
|
|
Baby, Feminine & Family Care
|
4,597
|
|
|
6
|
%
|
|
1,130
|
|
|
31
|
%
|
|
859
|
|
|
32
|
%
|
|
Corporate
|
116
|
|
|
N/A
|
|
|
(284)
|
|
|
N/A
|
|
|
43
|
|
|
N/A
|
|
|
Total Company
|
$
|
17,214
|
|
|
5
|
%
|
|
$
|
3,498
|
|
|
7
|
%
|
|
$
|
2,957
|
|
|
7
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended March 31, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales
|
|
% Change Versus Year Ago
|
|
Earnings/(Loss) Before Income Taxes
|
|
% Change Versus Year Ago
|
|
Net Earnings
|
|
% Change Versus Year Ago
|
|
Beauty
|
$
|
10,183
|
|
|
5
|
%
|
|
$
|
2,717
|
|
|
5
|
%
|
|
$
|
2,168
|
|
|
4
|
%
|
|
Grooming
|
4,559
|
|
|
(1)
|
%
|
|
1,225
|
|
|
3
|
%
|
|
1,018
|
|
|
(4)
|
%
|
|
Health Care
|
7,013
|
|
|
13
|
%
|
|
1,795
|
|
|
14
|
%
|
|
1,380
|
|
|
14
|
%
|
|
Fabric & Home Care
|
17,445
|
|
|
6
|
%
|
|
3,887
|
|
|
15
|
%
|
|
2,960
|
|
|
15
|
%
|
|
Baby, Feminine & Family Care
|
13,746
|
|
|
3
|
%
|
|
3,340
|
|
|
24
|
%
|
|
2,552
|
|
|
24
|
%
|
|
Corporate
|
306
|
|
|
N/A
|
|
|
(591)
|
|
|
N/A
|
|
|
239
|
|
|
N/A
|
|
|
Total Company
|
$
|
53,252
|
|
|
5
|
%
|
|
$
|
12,373
|
|
|
11
|
%
|
|
$
|
10,317
|
|
|
12
|
%
|
Beauty
Three months ended March 31, 2020 compared with three months ended March 31, 2019
Beauty net sales decreased 1% to $3.0 billion during the third fiscal quarter on a 1% increase in unit volume. Unfavorable product mix reduced net sales by 2% driven by the disproportionate decline of the super premium SKII brand, caused by the impacts of the COVD-19 pandemic related travel restrictions and economic downturns in Greater China and certain markets in Asia. Higher pricing increased net sales by 2%. Unfavorable foreign exchange impacts reduced net sales by 2%. Organic sales increased 1%. Global market share of the Beauty segment increased 0.2 points. The volume increase was driven by a double digit increase in Europe, a high single digit increase in Asia Pacific and a mid-single digit increase in North America, partially offset by a double digit decrease in Greater China (primarily due to reduced demand caused by the COVID-19 pandemic) and in IMEA.
•Volume in Hair Care decreased low single digits. The volume decrease was driven by a high teens decline in Greater China (due to the aforementioned negative impacts of COVID-19), a double digit decline in IMEA and a mid-single digits decline in North America (both due to market declines in certain countries). This was partially offset by a double digit volume increase in Europe and high single digit increase in Asia Pacific due to innovation. Global market share of the Hair Care category was unchanged.
•Volume in Skin and Personal Care increased high single digits, primarily driven by growth in personal care products. Volume grew double digits in North America, high single digits in Europe and Asia Pacific and mid-single digits in Greater China (all due to innovation, increased marketing spending and increased consumption and pantry loading due to the COVID-19 pandemic). Global market share of the Skin and Personal Care category increased less than half a point.
Net earnings decreased 21% to $436 million due to the decrease in net sales and a 360 basis-point decrease in net earnings margin. The net earnings margin decreased due to a reduction in gross margin, an increase in SG&A as a percentage of net sales and an increase in effective tax rates due to unfavorable geographic mix of earnings. The gross margin decrease was primarily driven by the negative impacts of unfavorable mix, due to the disproportionate decline of the super-premium SKII brand, partially offset by increased pricing. The increase in SG&A as a percentage of net sales was primarily due to the negative scale impacts of the net sales decrease and increased marketing spending.
Nine months ended March 31, 2020 compared with nine months ended March 31, 2019
Beauty fiscal year to date net sales increased 5% to $10.2 billion on a 3% increase in unit volume. Favorable product mix added 1% to net sales due to the disproportionate growth of the Skin and Personal Care category, including the Olay Skin care brand, which has higher than segment average selling prices. Higher pricing increased net sales by 2%. Unfavorable foreign exchange impacts reduced net sales by 2%. Organic sales increased 6%. Global market share of the Beauty segment increased 0.1 points. Volume grew high single digits in Europe, mid-single digits in Asia Pacific and low single digits in North America, Greater China and Latin America, partially offset by low single digit decrease in IMEA.
•Volume in Hair Care increased low single digits. Increased volume was driven by high single digits growth in Europe, mid-single digits growth in Asia Pacific and low single digits growth in Latin America due to product innovation and market growth, partially offset by a mid-single digit decline in Greater China (due to the aforementioned impacts of the COVID-19 pandemic) and a low single digit decline in IMEA (due to market decline in certain countries). Volume in North America was unchanged. Excluding the impact of minor acquisitions, organic volume in North America decreased low single digits due to market decline. Global market share of the Hair Care category was unchanged.
•Volume in Skin and Personal Care increased high single digits. Excluding the impact of minor brand acquisitions, organic volume increased mid-single digits. Volume growth was driven by a double digit increase in Greater China and mid-single digits increases in North America, Europe, Latin America and Asia Pacific. Volume growth was driven by innovation, increased marketing spending, market growth and to a lesser extent increased consumption and pantry loading in the most recent quarter due to the COVID-19 pandemic. Global market share of the Skin and Personal Care category increased less than half a point.
Net earnings increased 4% to $2.2 billion due to the increase in net sales, partially offset by a 10 basis-point decrease in net earnings margin. Net earnings margin decreased marginally due to a reduction in gross margin, offset by a reduction in SG&A as a percentage of net sales. The gross margin decrease was primarily driven by the negative impacts of unfavorable mix (due to the lower relative growth of the SK-II brand and the disproportionate growth of large sizes) and other hurts related to new manufacturing startup costs, partially offset by increased pricing. The reduction in SG&A as a percentage of net sales was primarily due to the positive scale impacts of the net sales increase.
Grooming
Three months ended March 31, 2020 compared with three months ended March 31, 2019
Grooming net sales decreased 3% to $1.4 billion during the third fiscal quarter on unit volume that was unchanged. Unfavorable foreign exchange had a negative 3% impact on net sales. Pricing had a positive 2% impact on net sales. Negative mix had a 2% unfavorable impact to net sales due to declines of the Appliances category and the North America region which have higher than segment average selling prices. Organic sales decreased 1%. Global market share of the Grooming segment increased 0.8 points. Mid-single digits volume increases in Asia Pacific, IMEA and Latin America, were offset by a mid-teens decline in Greater China primarily due to the impacts of the COVID-19 pandemic and a mid-single digits decline in North America.
•Shave Care volume was unchanged. Volume increased high single digits in Asia Pacific, increased mid-single digits in Latin America and increased low single digits in IMEA due to product innovation and increased distribution in certain markets. This was offset by a double digit decline in Greater China (due to the economic slowdown resulting from the COVID-19 pandemic) and a mid-single digits decline in North America (due to limited distribution capacity in light of the COVID-19 pandemic). Global market share of the Shave Care category increased slightly.
•Volume in Appliances decreased low single digits. Volume declined more than 30% in Greater China and declined high single digits in Asia Pacific due to the aforementioned COVID-19 impacts and competitive activity. This was partially offset by a more than 20% volume increase in IMEA, a high single digits increase in North America and a low single digits increase in Europe due to innovation and increased marketing spending in certain markets. Global market share of the Appliances category increased more than two points.
Net earnings decreased 26% to $254 million due to the decrease in net sales and a 570 basis-point decrease in net earnings margin. The net earnings margin declined primarily due to an increase in effective tax rates due to the benefit in the base period from the favorable adjustments to reserves for uncertain tax positions. To a lesser extent the net earnings margin was impacted by a reduction in gross margin and an increase in SG&A as a percentage of net sales. Gross margin decreased due to the negative impact of unfavorable mix (due to the disproportionate growth of disposable razor products and Asia Pacific and IMEA regions which have lower than segment average margins) and unfavorable foreign exchange impacts, partially offset by the benefits of manufacturing cost savings and increased selling prices. SG&A as a percentage of net sales increased due to the negative scale impacts of the net sales decline.
Nine months ended March 31, 2020 compared with nine months ended March 31, 2019
Grooming fiscal year to date net sales was $4.6 billion, a decrease of 1%, on unit volume that was unchanged. Unfavorable foreign exchange had a negative 2% impact on net sales. Pricing had a positive 2% impact on net sales. Unfavorable mix was a
negative 1% impact to net sales due to declines of the Appliances category and the North America region which have higher than segment average selling prices. Organic sales increased 1%. Global market share of the Grooming segment increased 0.3 points. A mid-single digits volume increase in Asia Pacific and low single digits increases in Europe, IMEA and Latin America were offset by mid-single digit declines in North America and in Greater China.
•Shave Care volume increased low single digits. The volume increase was driven by a double digit increase in Asia Pacific and low single digits increases in Europe, IMEA and Latin America due to product innovation, partially offset by a mid-single digits decline in North America and Greater China due to market decline and to a lesser extent, the impacts of the COVID-19 pandemic. Global market share of the Shave Care category was unchanged.
•Volume in Appliances decreased low single digits. A double digit decline in Asia Pacific and Greater China (due to market contraction, competitive activities and to a lesser extent the aforementioned impacts of the COVID-19 pandemic), was partially offset by mid-single digits volume increase in North America and low single digits increase in Europe due to innovation. Global market share of the Appliances category increased more than a point.
Net earnings decreased 4% to $1.0 billion due to the decrease in net sales and an 80 basis-point decrease in net earnings margin. Net earnings margin decreased primarily due to an increase in effective tax rates and to a lesser extent a reduction in gross margin, partially offset by a reduction in SG&A as a percentage of net sales. The increase in tax rates was due to the benefit in the base period from the favorable adjustments to reserves for uncertain tax positions. SG&A as a percentage of net sales decreased primarily due to a favorable legal settlement in the current period and a reduction in overhead costs due to productivity savings. Gross margin declined due to the negative impact of unfavorable mix (due to the disproportionate growth of disposable razor products and Asia Pacific and IMEA regions which have lower than segment average margins) and unfavorable foreign exchange impacts, partially offset by the benefits of manufacturing cost savings and increased selling prices.
Health Care
Three months ended March 31, 2020 compared with three months ended March 31, 2019
Health Care net sales increased 7% to $2.3 billion during the third fiscal quarter on a 7% increase in unit volume. Unfavorable foreign exchange impacts decreased net sales by 2%. Pricing had a 1% positive impact to net sales for the quarter. Favorable mix increased net sales by 1% due to the disproportionate growth of the Personal Health Care category and the North America region, both of which have higher than segment average selling prices. Organic sales increased 9%. Global market share of the Health Care segment increased 0.8 points. The volume increase was led by double digit growth in Latin America and IMEA and high single digits growth in Europe and North America. This was partially offset by a mid-teens decline in Greater China due primarily to the COVID-19 pandemic related economic slowdown.
•Oral Care volume increased mid-single digits. The volume increase was driven by over 20% growth in IMEA, mid-teens growth in Latin America, mid-single digits growth in Europe and low single digits growth in North America all driven by innovation and market growth. This was partially offset by a mid-teens volume decline in Greater China due to the economic slowdown related to the COVID-19 pandemic. Global market share of the Oral Care category increased less than a point.
•Volume in Personal Health Care increased double digits versus the prior year period. The volume increase was driven by high teens growth in North America, mid-teens growth in Europe, high single digits growth in Latin America, and mid-single digits growth in IMEA, driven by innovation, increased marketing spending and increased consumption and pantry loading due to the COVID-19 pandemic. Global market share of the Personal Health Care category increased a point.
Net earnings increased 14% to $408 million, due to the increase in net sales and a 110 basis-points increase in net earnings margin. Net earnings margin increased due to an increase in gross margin and a decrease in SG&A as a percentage of net sales. The increase in gross margin was driven by the positive impacts of manufacturing cost savings and increased pricing, partially offset by unfavorable mix impact due to the disproportionate growth of certain markets in IMEA with lower than segment average margins. SG&A as a percentage of net sales decreased primarily due to the positive scale benefits of the net sales increase and a reduction in overhead costs due to productivity savings.
Nine months ended March 31, 2020 compared with nine months ended March 31, 2019
Health Care fiscal year to date net sales increased 13% to $7.0 billion on a 13% increase in unit volume. Excluding the impact of the Merck OTC consumer healthcare acquisition, organic sales increased 8% and organic volume increased 7%. Unfavorable foreign exchange impacts reduced net sales by 2%. Higher pricing increased net sales by 1%. Favorable mix increased net sales by 1% due to the disproportionate organic growth of the Personal Health Care category which has higher than segment average margins. Global market share of the Health Care segment increased 0.6 points. The volume increase was led by over 30% growth in IMEA, high teens growth in Latin America, mid-teens growth in Europe, double digit growth in Asia Pacific and high single digits growth in North America, partially offset by mid-single digits decrease in Greater China. Excluding the impact of the Merck OTC consumer healthcare acquisition, organic volume increased mid-teens in IMEA, increased high single digits in Latin America, increased mid-single digits in Europe and increased low single digits in Asia Pacific.
•Oral Care volume increased mid-single digits. Increased volume was driven by over 20% growth in IMEA, double digits growth in Latin America, mid-single digits growth in Asia Pacific and North America and low single digits growth in Europe, all due to innovation and market growth. Excluding the impact of minor divestitures, volume in Europe grew mid-single digits. Growth in these markets was partially offset by a mid-single digits volume decrease in Greater China due to the economic slowdown related to the COVID-19 pandemic in the most recent quarter and competitive activities. Global market share of the Oral Care category increased half a point.
•Volume in Personal Health Care increased more than 30% versus the prior period. Excluding the impact of the Merck OTC consumer healthcare acquisition, organic volume increased double digits. The organic volume increase was driven by mid-teens growth in Europe and double digits growth in North America (both due to innovation, increased marketing spending, and to a lesser extent the increased consumption and pantry loading due to the COVID-19 pandemic), a high single digits growth in IMEA and mid-single digits growth in Latin America (both due to innovation and increased marketing spending) partially offset by a low single digits decline in Asia Pacific due to devaluation-related price increases. Global market share of the Personal Health Care category increased more than half a point.
Net earnings increased 14% to $1.4 billion due to the increase in net sales and a 10 basis-points increase in net earnings margin. Net earnings margin increased due to an increase in gross margin partially offset by an increase in SG&A as a percentage of net sales. The increase in gross margin was driven primarily by the positive impacts of increased pricing and manufacturing cost savings. SG&A as a percentage of net sales increased primarily due to an increase in overheads and other operating expenses primarily caused by the Merck OTC consumer healthcare acquisition, partially offset by the positive scale benefits of the net sales increase.
Fabric & Home Care
Three months ended March 31, 2020 compared with three months ended March 31, 2019
Fabric & Home Care net sales increased 8% to $5.8 billion during the third fiscal quarter on an 8% increase in unit volume. Unfavorable foreign exchange impacts reduced net sales by 1%. Positive mix impacts increased net sales by 1% due to the disproportionate growth of the Home Care category, which has higher than segment average prices. Pricing had no net impact to net sales. Organic sales increased 10%. Global market share of the Fabric & Home Care segment increased 0.7 points. Volume growth was driven by double digit increases in North America and Latin America, a high single digit increase in Europe and a mid-single digit increase in Asia Pacific, partially offset by a double digit volume decrease in Greater China, primarily due to the economic slow down related to the COVID-19 pandemic. The volume increases in North America and Europe were partially due to increased consumption and pantry loading related to the COVID-19 pandemic.
•Fabric Care volume increased high single digits. Increased volume was driven by mid-teens growth in North America, double digit growth in Latin America, high single digits growth in Europe and mid-single digits growth in Asia Pacific, all due to product innovation and the aforementioned consumption increase in certain markets related to the COVID-19 pandemic. This was partially offset by a double digits decline in Greater China due to the COVID-19 related economic slowdown. Global market share of the Fabric Care category increased more than half a point.
•Home Care volume increased double digits. Volume increased in all regions led by a mid-teens growth in Europe, high single digits growth in North America and mid-single digits growth in Asia Pacific and Latin America, all due to product innovation and the aforementioned consumption increase in certain markets related to the COVID-19 pandemic. Excluding the impact of minor divestitures, volume in Latin America grew high single digits. Global market share of the Home Care category increased nearly a point.
Net earnings increased 13% to $957 million due to the increase in net sales and a 70 basis-points increase in net earnings margin. The net earnings margin increase was primarily due to an increase in gross margin, partially offset by a higher effective tax rate. The gross margin increase was driven by manufacturing cost savings and a reduction in commodity costs, partially offset by unfavorable product mix due to the disproportionate growth of premium innovation that has not yet been cost optimized. The higher effective tax rate was due to the disproportionate growth in North America. SG&A as a percentage of net sales increased marginally due primarily to higher marketing spending, partially offset by the positive scale benefits of the net sales increase.
Nine months ended March 31, 2020 compared with nine months ended March 31, 2019
Fabric & Home Care fiscal year to date net sales increased 6% to $17.4 billion on a 6% increase in unit volume. Unfavorable foreign exchange impacts reduced net sales by 1%. Positive mix impacts increased net sales by 1% due to the disproportionate growth of premium products, including unit dose laundry and fabric enhancers. Pricing had no impact to net sales for the period. Organic sales increased 7%. Global market share of the Fabric & Home Care segment increased 0.7 points. The volume growth was driven by a double digit increase in Latin America, a high single digits increase in North America, along with mid-single digit increases in Europe and Asia Pacific and a low single digit increase in Greater China.
•Fabric Care volume increased mid-single digits. The volume increase was led by double digits growth in Latin America and high single digits growth in North America, along with mid-single digits growth in Europe and low single digits
growth in Asia Pacific and Greater China. Volume growth was driven by product innovation and to a lesser extent the aforementioned consumption increase due to the COVID-19 pandemic. Global market share of the Fabric Care category increased more than half a point.
•Home Care volume increased mid-single digits. Volume increased in all regions led by double digits growth in Europe, mid-single digits growth in Asia Pacific and North America and low single digits growth in IMEA and Latin America due to product innovation and to a lesser extent the aforementioned consumption increase due to the COVID-19 pandemic. Excluding the impact of minor divestitures, volume increased mid-single digits in Latin America. Global market share of the Home Care category increased more than a point.
Net earnings increased 15% to $3.0 billion due to the increase in net sales and a 130 basis-points increase in net earnings margin. The net earnings margin increase was primarily due to an increase in gross margin, along with a marginal reduction in SG&A as a percentage of net sales. The gross margin increase was driven primarily by manufacturing cost savings and reduction in commodity costs. SG&A expense as a percentage of net sales decreased due to the positive scale benefits of the net sales increase, partially offset by an increase in marketing spending.
Baby, Feminine & Family Care
Three months ended March 31, 2020 compared with three months ended March 31, 2019
Baby, Feminine & Family Care net sales increased 6% to $4.6 billion during the third fiscal quarter on a 7% increase in unit volume. Unfavorable foreign exchange impacts decreased net sales by 1%. Pricing and mix had no impact to net sales. Organic sales increased 7%. Global market share of the Baby, Feminine & Family Care segment decreased 0.3 points. Volume increased double digits in North America and high single digits in Europe, both driven primarily by increased consumption and pantry loading due to the COVID-19 pandemic, and increased mid-single digits in Asia Pacific. This was partially offset by a double digit volume decrease in Greater China due to the economic slowdown related to the COVID-19 pandemic, a high single digit decrease in Latin America and a mid-single digits decrease in IMEA.
•Volume in Baby Care was unchanged. Volume decreased double digits in Greater China (primarily due to the COVID-19 related economic slowdown) and in Latin America (due to market contraction and increased pricing) and decreased high single digits in IMEA (due to the COVID-19 related economic slowdown and competitive activity). This was offset by mid-single digits growth in North America (due to the aforementioned consumption increase and pantry loading related to the COVID-19 pandemic, market growth and increased marketing spending) and Asia Pacific (due to innovation) and low single digit growth in Europe (due to the pantry loading related to the COVID-19 pandemic). Global market share of the Baby Care category decreased more than a point.
•Volume in Feminine Care increased high single digits. Excluding the impacts of a minor acquisition, organic volume increased mid-single digits. Volume increased over 20% in Asia Pacific due to a new launch in the adult incontinence category in Japan. Volume increased mid-teens in Europe and mid-single digits in North America due to the aforementioned pantry loading related to the COVID-19 pandemic, product innovation, and increased marketing spending. This was partially offset by a double digit decline in Greater China due to the COVID-19 related economic slowdown. Global market share of the Feminine Care category increased more than half a point.
•Volume in Family Care, which is predominantly a North American business, increased mid-teens driven by the COVID-19 related consumption increase and pantry loading and increased marketing spending. North America share of the Family Care category was unchanged.
Net earnings increased 32% to $859 million due to the increase in net sales and a 370 basis-point increase in net earnings margin. Net earnings margin increased primarily due to an increase in gross margin, partially offset by a marginal increase in SG&A as a percentage of net sales. Gross margin increased due to manufacturing cost savings and a reduction in commodity costs, partially offset by negative mix impacts due to the disproportionate growth of large sizes and product forms with lower than segment-average margins. SG&A as a percentage of net sales increased marginally due to an increase in marketing spending as a percentage of sales, partially offset by reduced overhead costs, driven by productivity savings and the positive scale benefits of the net sales increase.
Nine months ended March 31, 2020 compared with nine months ended March 31, 2019
Baby, Feminine & Family Care fiscal year to date net sales increased 3% to $13.7 billion on a 3% increase in unit volume. Unfavorable foreign exchange impacts reduced net sales by 1%. Higher pricing increased net sales by 1%. Mix did not have a net impact on net sales. Organic sales increased 4%. Global market share of the Baby, Feminine & Family Care segment decreased 0.4 points. Volume growth was driven by mid-single digit increases in North America and Asia Pacific and a low single digit increase in Europe, partially offset by mid-single digit decline in Latin America and low single digit decline in Greater China and IMEA.
•Volume in Baby Care decreased low single digits. Volume decreased high single digits in Latin America, mid-single digits in Greater China and IMEA, and low single digits in Europe due to competitive activity, devaluation related price increases, category contraction in certain markets and to a lesser extent the aforementioned impacts of the COVID-19
pandemic. This was partially offset by low single digit volume increases in North America and Asia Pacific due to product innovation, market growth and to a lesser extent the increased consumption and pantry loading due to the COVID-19 pandemic. Global market share of the Baby Care category decreased more than a point.
•Volume in Feminine Care increased mid-single digits. The volume increase was led by a double digit increase in Asia Pacific due to new launch in the adult incontinence category in Japan, a high single digits increase in Europe and mid-single digit increases in North America and Latin America, due to product innovation, increased marketing spending, adult incontinence category growth and to a lesser extent pantry loading due to the COVID-19 pandemic. Excluding the impact of a minor acquisition, North America volume increased low single digits. Global market share of the Feminine Care category increased nearly half a point.
•Volume in Family Care, which is predominantly a North American business, increased high single digits driven by the aforementioned COVID-19 related consumption increase and pantry loading, product innovation, market growth and increased marketing spending. North America share of the Family Care category was unchanged.
Net earnings increased 24% to $2.6 billion due to the increase in net sales and a 320 basis-point increase in net earnings margin. Net earnings margin increased due to an increase in gross margin, partially offset by a marginal increase in SG&A as a percentage of net sales. Gross margin increased due to manufacturing cost savings projects, a reduction in commodity costs and increased selling prices, partially offset by negative mix impacts due to the disproportionate growth of large sizes and product forms with lower than segment-average margins. SG&A as a percentage of net sales increased marginally due to an increase in marketing spending as a percentage of sales, partially offset by reduced overhead costs, driven by productivity savings and the positive scale benefits of the net sales increase.
Corporate
Corporate includes certain operating and non-operating activities not allocated to specific business segments. These include: the incidental businesses managed at the corporate level; financing and investing activities; certain employee benefit costs; other general corporate items; the gains and losses related to certain divested brands and categories; and certain restructuring-type activities to maintain a competitive cost structure, including manufacturing and workforce optimization. Corporate also includes reconciling items to adjust the accounting policies used in the reportable segments to U.S. GAAP. The most significant reconciling item includes income taxes to adjust from blended statutory rates that are reflected in the reportable segments to the overall Company effective tax rate.
Corporate net sales decreased $7 million to $116 million for the quarter ended March 31, 2020 and decreased $62 million to $306 million for the fiscal year to date. Corporate net earnings improved by $20 million in the quarter primarily due to discrete tax benefits during the quarter that are not allocated to the segment, partially offset by higher restructuring charges, all of which have been described above. Fiscal year to date Corporate net earnings increased $26 million as tax benefits and lower interest expense in the current period were largely offset by the base period gain on the dissolution of the PGT Healthcare partnership.
Restructuring Program to deliver Productivity and Cost Savings
In 2012, the Company initiated a productivity and cost savings plan to reduce costs and better leverage scale in the areas of supply chain, research and development, marketing and overheads. The plan was designed to accelerate cost reductions by streamlining management decision making, manufacturing and other work processes to fund the Company's growth strategy. In 2017, the Company communicated specific elements of an additional multi-year productivity and cost savings program.
The current productivity and cost savings plan is expected to further reduce costs in the areas of supply chain, certain marketing activities and overhead expenses. As part of this plan, the Company incurred $1.8 billion in total before-tax restructuring costs across fiscal 2018 and fiscal 2019, with an additional amount of $0.5 to $0.6 billion expected in fiscal 2020. This program is expected to result in additional targeted enrollment reductions, along with further optimization of the supply chain and other manufacturing processes. Consistent with our historical policies for ongoing restructuring-type activities, the resulting charges are funded by and included within Corporate for segment reporting.
In addition to our restructuring programs, we have additional ongoing savings efforts in our supply chain, marketing and overhead areas that have and are expected to continue to yield additional benefits to our operating margins.
Refer to Note 9 in the Notes to the Consolidated Financial Statements for more details on the restructuring program.
LIQUIDITY & CAPITAL RESOURCES
Operating Activities
We generated $12.6 billion of cash from operating activities fiscal year to date, an increase of $1.5 billion versus the prior year. Net earnings, adjusted for non-cash items (depreciation and amortization, share-based compensation expense, deferred income taxes and loss on sale of assets), generated $12.3 billion of operating cash flow. Working capital and other impacts generated $333 million of cash in the period. Accounts receivable decreased, generating $135 million of cash, primarily due to the timing of the quarter-end (which fell on a Tuesday versus Sunday in the prior year end, resulting in additional collection days in the current year). Inventory increased, consuming $533 million of cash primarily to support business growth, including increased manufacturing to help build safety stocks to help manage through the COVID-19 pandemic and product initiatives. Accounts payable, accrued and other liabilities increased, generating $738 million of cash. Taxes payable accounted for approximately $400 million of this amount, primarily due to an approximate $500 million increase related to the integration of Merck, which had no impact on operating cash flows, as there was an equal and offsetting release of a deferred tax liability that was initially created on the acquisition of Merck. Extended payment terms to suppliers generated approximately $475 million of cash and all other accruals used approximately $140 million. All other operating assets and liabilities used $58 million of cash.
Investing Activities
Investing activities generated $3.7 billion of cash fiscal year to date. Capital expenditures were $2.4 billion, or 4.5% of net sales. We received $6.2 billion of cash from sales and maturities of investment securities.
Financing Activities
Our financing activities used $5.0 billion of net cash fiscal year to date. We used $7.4 billion for treasury stock purchases, $5.8 billion for dividends and $1.5 billion for debt repayments. Cash from the issuance of bonds and commercial paper generated $5.0 billion and $3.0 billion of cash, respectively, and the exercise of stock options and other impacts generated $1.8 billion of cash.
As of March 31, 2020, our current liabilities exceeded current assets by $5.8 billion. We have short- and long-term debt to meet our financing needs. We anticipate being able to support our short-term liquidity and operating needs largely through cash generated from operations. We have strong short- and long-term debt ratings that have enabled and should continue to enable us to refinance our debt as it becomes due at favorable rates in commercial paper and bond markets. In addition, we have agreements with a diverse group of financial institutions that, if needed, should provide sufficient credit funding to meet short-term financing requirements.
RECONCILIATION OF MEASURES NOT DEFINED BY U.S. GAAP
In accordance with the SEC's Regulation S-K Item 10(e), the following provides definitions of the non-GAAP measures and the reconciliation to the most closely related GAAP measures. We believe that these measures provide useful perspective on underlying business results and trends (i.e., trends excluding non-recurring or unusual items) and provide a supplemental measure of year-on-year results. The non-GAAP measures described below are used by management in making operating decisions, allocating financial resources and for business strategy purposes. These measures may be useful to investors as they provide supplemental information about business performance and provide investors a view of our business results through the eyes of management. These measures are also used to evaluate senior management and are a factor in determining their at-risk compensation. These non-GAAP measures are not intended to be considered by the user in place of the related GAAP measure, but rather as supplemental information to our business results. These non-GAAP measures may not be the same as similar measures used by other companies due to possible differences in method and in the items or events being adjusted.
Organic sales growth: Organic sales growth is a non-GAAP measure of sales growth excluding the impacts of acquisitions and divestitures and foreign exchange from year-over-year comparisons. We believe this measure provides investors with a supplemental understanding of underlying sales trends by providing sales growth on a consistent basis. This measure is used in assessing achievement of management goals for at-risk compensation.
Adjusted free cash flow: Adjusted free cash flow is defined as operating cash flow less capital spending and excluding payments for the transitional tax resulting from the comprehensive U.S. legislation commonly referred to as the Tax Cuts and Jobs Act enacted in December 2017 (the U.S. Tax Act). Adjusted free cash flow represents the cash that the Company is able to generate after taking into account planned maintenance and asset expansion. Management views adjusted free cash flow as an important measure because it is one factor used in determining the amount of cash available for dividends, share repurchases, acquisitions and other discretionary investments.
Adjusted free cash flow productivity: Adjusted free cash flow productivity is defined as the ratio of adjusted free cash flow to net earnings. Management views adjusted free cash flow productivity as a useful measure to help investors understand P&G’s ability to generate cash. Adjusted free cash flow productivity is used by management in making operating decisions, allocating financial resources and for budget planning purposes. This measure is also used in assessing the achievement of management goals for at-risk compensation. The Company's long-term target is to generate annual adjusted free cash flow productivity at or above 90 percent.
Core EPS: Core earnings per share, or Core EPS, is a measure of the Company's diluted net earnings per share adjusted as indicated. Management views this non-GAAP measure as a useful supplemental measure of Company performance over time. This measure is also used when evaluating senior management in determining their at-risk compensation.
The Core earnings measures included in the following reconciliation tables refer to the equivalent GAAP measures adjusted as applicable for the following items:
Incremental Restructuring: The Company has had and continues to have an ongoing level of restructuring activities. Such activities have resulted in ongoing annual restructuring related charges of approximately $250 - $500 million before tax. In 2012, the Company began a $10 billion strategic productivity and cost savings initiative that included incremental restructuring activities. In 2017, we communicated details of an additional multi-year productivity and cost savings plan. This results in incremental restructuring charges to accelerate productivity efforts and cost savings. The adjustment to Core earnings includes only the restructuring costs above what we believe are the normal recurring level of restructuring costs.
Gain on Dissolution of PGT Healthcare Partnership: The Company finalized the dissolution of our PGT Healthcare partnership, a venture between the Company and Teva Pharmaceuticals Industries, Ltd. (Teva) in the OTC consumer healthcare business, in the quarter ended September 30, 2018. The transaction was accounted for as a sale of the Teva portion of the PGT business and resulted in the Company recognizing an after-tax gain on the dissolution of $353 million.
We do not view the above items to be part of our sustainable results and their exclusion from Core earnings measures provides a more comparable measure of year-on-year results. These items are also excluded when evaluating senior management in determining their at-risk compensation.
Organic sales growth:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2020
|
Net Sales Growth
|
|
Foreign Exchange Impact
|
|
Acquisition & Divestiture Impact/Other (1)
|
|
Organic Sales Growth
|
|
Beauty
|
(1)%
|
|
|
2%
|
|
|
—%
|
|
|
1%
|
|
|
Grooming
|
(3)%
|
|
|
3%
|
|
|
(1)%
|
|
|
(1)%
|
|
|
Health Care
|
7%
|
|
|
2%
|
|
|
—%
|
|
|
9%
|
|
|
Fabric & Home Care
|
8%
|
|
|
1%
|
|
|
1%
|
|
|
10%
|
|
|
Baby, Feminine & Family Care
|
6%
|
|
|
1%
|
|
|
—%
|
|
|
7%
|
|
|
Total Company
|
5%
|
|
|
2%
|
|
|
(1)%
|
|
|
6%
|
|
(1)Includes rounding impacts necessary to reconcile net sales to organic sales.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended March 31, 2020
|
Net Sales Growth
|
|
Foreign Exchange Impact
|
|
Acquisition & Divestiture Impact/Other (1)
|
|
Organic Sales Growth
|
|
Beauty
|
5%
|
|
|
2%
|
|
|
(1)%
|
|
|
6%
|
|
|
Grooming
|
(1)%
|
|
|
2%
|
|
|
—%
|
|
|
1%
|
|
|
Health Care
|
13%
|
|
|
2%
|
|
|
(7)%
|
|
|
8%
|
|
|
Fabric & Home Care
|
6%
|
|
|
1%
|
|
|
—%
|
|
|
7%
|
|
|
Baby, Feminine & Family Care
|
3%
|
|
|
1%
|
|
|
—%
|
|
|
4%
|
|
|
Total Company
|
5%
|
|
|
2%
|
|
|
(1)%
|
|
|
6%
|
|
(1)Includes rounding impacts necessary to reconcile net sales to organic sales.
Adjusted free cash flow (dollar amounts in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended March 31, 2020
|
|
|
|
|
|
|
Operating Cash Flow
|
|
Capital Spending
|
U.S. Tax Act Payments
|
|
Adjusted Free Cash Flow
|
|
$12,597
|
|
|
$(2,415)
|
|
$215
|
|
|
$10,397
|
|
Adjusted free cash flow productivity (dollar amounts in millions):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended March 31, 2020
|
|
|
|
|
|
Adjusted Free Cash Flow
|
|
Net Earnings
|
|
Adjusted Free Cash Flow Productivity
|
|
$10,397
|
|
|
$10,317
|
|
|
101%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
(Amounts in Millions Except Per Share Amounts)
Reconciliation of Non-GAAP Measures
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2020
|
|
|
|
|
|
|
|
|
|
AS REPORTED (GAAP)
|
|
INCREMENTAL RESTRUCTURING (2)
|
|
ROUNDING
|
|
NON-GAAP (CORE)
|
|
COST OF PRODUCTS SOLD
|
$
|
8,716
|
|
|
$
|
(179)
|
|
|
$
|
—
|
|
|
$
|
8,537
|
|
|
SELLING, GENERAL AND ADMINISTRATIVE EXPENSE
|
5,045
|
|
|
26
|
|
|
—
|
|
|
5,071
|
|
|
OPERATING INCOME
|
3,453
|
|
|
153
|
|
|
—
|
|
|
3,606
|
|
|
INCOME TAX
|
541
|
|
|
15
|
|
|
—
|
|
|
556
|
|
|
NET EARNINGS ATTRIBUTABLE TO P&G
|
2,917
|
|
|
141
|
|
|
—
|
|
|
3,058
|
|
|
|
|
|
|
|
|
|
Core EPS
|
|
|
DILUTED NET EARNINGS PER COMMON SHARE (1)
|
$
|
1.12
|
|
|
$
|
0.05
|
|
|
$
|
—
|
|
|
$
|
1.17
|
|
(1)Diluted net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
(2) While total restructuring costs exceeded the historical ongoing level, total restructuring costs included within SG&A for this period were below the historical ongoing level. Accordingly, the non-GAAP adjustment for the SG&A line item adds costs to the comparable GAAP number.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CHANGE VERSUS YEAR AGO
|
|
|
|
|
|
|
|
CORE NET EARNINGS ATTRIBUTABLE TO P&G
|
10
|
%
|
|
|
|
|
|
|
CORE EPS
|
10
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
(Amounts in Millions Except Per Share Amounts)
Reconciliation of Non-GAAP Measures
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended March 31, 2019
|
|
|
|
|
|
|
|
|
|
|
|
AS REPORTED (GAAP)
|
|
INCREMENTAL RESTRUCTURING (2)
|
|
|
|
ROUNDING
|
|
NON-GAAP (CORE)
|
|
COST OF PRODUCTS SOLD
|
$
|
8,427
|
|
|
$
|
(65)
|
|
|
|
|
$
|
—
|
|
|
$
|
8,362
|
|
|
SELLING, GENERAL AND ADMINISTRATIVE EXPENSE
|
4,806
|
|
|
18
|
|
|
|
|
(1)
|
|
|
4,823
|
|
|
OPERATING INCOME
|
3,229
|
|
|
47
|
|
|
|
|
1
|
|
|
3,277
|
|
|
INCOME TAX
|
502
|
|
|
7
|
|
|
|
|
—
|
|
|
509
|
|
|
NET EARNINGS ATTRIBUTABLE TO P&G
|
2,745
|
|
|
44
|
|
|
|
|
—
|
|
|
2,789
|
|
|
|
|
|
|
|
|
|
|
|
Core EPS
|
|
|
DILUTED NET EARNINGS PER COMMON SHARE (1)
|
$
|
1.04
|
|
|
$
|
0.02
|
|
|
|
|
$
|
—
|
|
|
$
|
1.06
|
|
(1)Diluted net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
(2) While total restructuring costs exceeded the historical ongoing level, total restructuring costs included within SG&A for this period were below the historical ongoing level. Accordingly, the non-GAAP adjustment for the SG&A line item adds costs to the comparable GAAP number.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
(Amounts in Millions Except Per Share Amounts)
Reconciliation of Non-GAAP Measures
|
|
|
|
|
|
|
|
|
Nine Months Ended March 31, 2020
|
|
|
|
|
|
|
|
|
|
AS REPORTED (GAAP)
|
|
INCREMENTAL RESTRUCTURING (2)
|
|
ROUNDING
|
|
NON-GAAP (CORE)
|
|
COST OF PRODUCTS SOLD
|
26,308
|
|
|
$
|
(273)
|
|
|
$
|
—
|
|
|
$
|
26,035
|
|
|
SELLING, GENERAL AND ADMINISTRATIVE EXPENSE
|
14,719
|
|
|
73
|
|
|
—
|
|
|
14,792
|
|
|
OPERATING INCOME
|
12,225
|
|
|
200
|
|
|
—
|
|
|
12,425
|
|
|
INCOME TAX
|
2,056
|
|
|
20
|
|
|
1
|
|
|
2,077
|
|
|
NET EARNINGS ATTRIBUTABLE TO P&G
|
10,227
|
|
|
189
|
|
|
—
|
|
|
10,416
|
|
|
|
|
|
|
|
|
|
Core EPS
|
|
|
DILUTED NET EARNINGS PER COMMON SHARE (1)
|
$
|
3.89
|
|
|
$
|
0.07
|
|
|
$
|
—
|
|
|
$
|
3.96
|
|
(1)Diluted net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
(2)While total restructuring costs exceeded the historical ongoing level, total restructuring costs included within SG&A for this period were below the historical ongoing level. Accordingly, the non-GAAP adjustment for the SG&A line item adds costs to the comparable GAAP number.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CHANGE VERSUS YEAR AGO
|
|
|
|
|
|
|
|
CORE NET EARNINGS ATTRIBUTABLE TO P&G
|
16
|
%
|
|
|
|
|
|
|
CORE EPS
|
16
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
(Amounts in Millions Except Per Share Amounts)
Reconciliation of Non-GAAP Measures
|
|
|
|
|
|
|
|
|
|
|
Nine Months Ended March 31, 2019
|
|
|
|
|
|
|
|
|
|
|
|
AS REPORTED (GAAP)
|
|
INCREMENTAL RESTRUCTURING (2)
|
|
GAIN ON DISSOLUTION OF PGT PARTNERSHIP
|
|
ROUNDING
|
|
NON-GAAP (CORE)
|
|
COST OF PRODUCTS SOLD
|
$
|
25,830
|
|
|
$
|
(234)
|
|
|
$
|
—
|
|
|
$
|
—
|
|
|
$
|
25,596
|
|
|
SELLING, GENERAL AND ADMINISTRATIVE EXPENSE
|
14,081
|
|
|
28
|
|
|
—
|
|
|
(1)
|
|
|
14,108
|
|
|
OPERATING INCOME
|
10,679
|
|
|
206
|
|
|
—
|
|
|
1
|
|
|
10,886
|
|
|
INCOME TAX
|
1,931
|
|
|
30
|
|
|
(2)
|
|
|
(1)
|
|
|
1,958
|
|
|
NET EARNINGS ATTRIBUTABLE TO P&G
|
9,138
|
|
|
190
|
|
|
(353)
|
|
|
1
|
|
|
8,976
|
|
|
|
|
|
|
|
|
|
|
|
Core EPS
|
|
|
DILUTED NET EARNINGS PER COMMON SHARE (1)
|
$
|
3.48
|
|
|
$
|
0.07
|
|
|
$
|
(0.13)
|
|
|
$
|
—
|
|
|
$
|
3.42
|
|
(1)Diluted net earnings per share are calculated on Net earnings attributable to Procter & Gamble.
(2)While total restructuring costs exceeded the historical ongoing level, total restructuring costs included within SG&A for this period were below the historical ongoing level. Accordingly, the non-GAAP adjustment for the SG&A line item adds costs to the comparable GAAP number.